Amended Annual and Transition Report (foreign Private Issuer) (20-f/a)

0.2170.0600.0580.0190.0190.2150.0600.0580.0190.0580.0600.2170.0190.0580.0600.2150.002553000000.0610.0580.0600.2200.2170.600.0030.0030.0030.0020.600.2180.2150.0600.0600.05813.80113.98112.08312.45113.60412.80212.88911.37811.31411.85213.04413.29616.42116.9916.9913.3713.9713.9714.3512.4511.5711.5711.5711.5213.4115.0813.4513.9712.46612.5113.3712.51falseFY--12-3100014920740.1270.0580.1270.0580.0020.0020.0020.002See note 1(d) for details related to the retrospective impact of a change in the Group’s accounting policy for cloud computing costs.Within cash and cash equivalents at 31 December 2021 is £nil (31 December 2020: £1.3m; 30 June 2020: £0.9m; 30 June 2019: £0.4m) of cash relating to employee contributions to the Group’s share scheme ‘AbShare’, which is reserved for the purpose of purchasing shares upon vesting. 0001492074 2021-12-31 0001492074 2020-12-31 0001492074 2020-06-30 0001492074 2021-01-01 2021-12-31 0001492074 2020-07-01 2020-12-31 0001492074 2019-07-01 2020-06-30 0001492074 2018-07-01 2019-06-30 0001492074 2019-06-30 0001492074 2020-04-09 0001492074 2018-07-01 0001492074 2020-06-30 2020-06-30 0001492074 2020-01-01 2020-12-31 0001492074 2020-01-01 2020-06-30 0001492074 2019-01-01 2019-06-30 0001492074 2019-07-01 2019-12-31 0001492074 2018-06-30 0001492074 2019-12-31 0001492074 abcm:RetirementBenefitSchemesMember 2021-12-31 0001492074 abcm:BioVisionCguMember 2021-12-31 0001492074 abcm:GroupCguMember 2021-12-31 0001492074 abcm:BiovisionBusinessMember 2021-12-31 0001492074 abcm:EquinitiSharePlanTrusteesLimitedMember 2021-12-31 0001492074 abcm:ExpedeonCaptsureTechnologyMember 2021-12-31 0001492074 abcm:ExpedeonAntibodyLabellingAndConjugationTechnologyMember 2021-12-31 0001492074 abcm:EpitomicsRabMabTechnologyMember 2021-12-31 0001492074 abcm:FireflyBioworksMultiplexAndAssayTechnologyMember 2021-12-31 0001492074 abcm:RocheLicenceAgreementMember 2021-12-31 0001492074 abcm:BioVisionMetabolismAssaysAndProteinsMember 2021-12-31 0001492074 ifrs-full:JointControlOrSignificantInfluenceMember 2021-12-31 0001492074 ifrs-full:TopOfRangeMember ifrs-full:JointControlOrSignificantInfluenceMember 2021-12-31 0001492074 abcm:CashAndCashEquivalentsMember 2021-12-31 0001492074 ifrs-full:LeaseLiabilitiesMember 2021-12-31 0001492074 ifrs-full:ShorttermBorrowingsMember 2021-12-31 0001492074 ifrs-full:NotLaterThanOneYearMember 2021-12-31 0001492074 ifrs-full:LaterThanOneYearMember 2021-12-31 0001492074 abcm:BioVisionAcquisitionMember 2021-12-31 0001492074 abcm:BioVisionBusinessMember 2021-12-31 0001492074 abcm:LaterThenOneYearAndNotLaterThenFiveYearsMember 2021-12-31 0001492074 ifrs-full:LaterThanFiveYearsMember 2021-12-31 0001492074 abcm:RestOfAsiaPacificMember 2021-12-31 0001492074 country:JP 2021-12-31 0001492074 country:CN 2021-12-31 0001492074 abcm:EmeaMember 2021-12-31 0001492074 abcm:TheAmericasMember 2021-12-31 0001492074 abcm:CalicoAcquisitionMember 2021-12-31 0001492074 ifrs-full:GrossCarryingAmountMember 2021-12-31 0001492074 abcm:OptionsMember 2021-12-31 0001492074 abcm:NotDesignatedAsHedgingInstrumentMember ifrs-full:AtFairValueMember 2021-12-31 0001492074 abcm:DesignatedAsHedgingInstrumentMember ifrs-full:ForwardContractMember 2021-12-31 0001492074 abcm:ThousandAndTwentyPMember 2021-12-31 0001492074 abcm:EightHundredAndFiftyOnePMember 2021-12-31 0001492074 abcm:FiveHundredAndNinetyEightPMember 2021-12-31 0001492074 abcm:HundredAndEightyPointEightyPToFourHundredAndSixtyFourPMember ifrs-full:TopOfRangeMember 2021-12-31 0001492074 abcm:HundredAndEightyPointEightyPToFourHundredAndSixtyFourPMember ifrs-full:BottomOfRangeMember 2021-12-31 0001492074 abcm:HundredAndEightyPointEightyPToFourHundredAndSixtyFourPMember 2021-12-31 0001492074 abcm:LaterThanSixtyDaysMember abcm:PastDueMember 2021-12-31 0001492074 abcm:PastDueMember 2021-12-31 0001492074 abcm:PastDueMember ifrs-full:GrossCarryingAmountMember 2021-12-31 0001492074 abcm:NotPastDueMember ifrs-full:GrossCarryingAmountMember 2021-12-31 0001492074 abcm:NotPastDueMember 2021-12-31 0001492074 abcm:NotLaterThanThirtyDaysMember abcm:PastDueMember ifrs-full:GrossCarryingAmountMember 2021-12-31 0001492074 abcm:NotLaterThanThirtyDaysMember abcm:PastDueMember 2021-12-31 0001492074 abcm:LaterThanThirtyDaysAndNotLaterThanSixtyDaysMember abcm:PastDueMember ifrs-full:GrossCarryingAmountMember 2021-12-31 0001492074 abcm:LaterThanThirtyDaysAndNotLaterThanSixtyDaysMember abcm:PastDueMember 2021-12-31 0001492074 abcm:LaterThanSixtyDaysMember abcm:PastDueMember ifrs-full:GrossCarryingAmountMember 2021-12-31 0001492074 abcm:ShareIncentivePlanAwardsMember abcm:FreeSharesMember 2021-12-31 0001492074 abcm:ProfitableGrowthIncentivePlanAwardsMember 2021-12-31 0001492074 abcm:ShareIncentivePlanAwardsMember abcm:MatchingSharesMember 2021-12-31 0001492074 abcm:AbShareAwardsMember 2021-12-31 0001492074 abcm:LongTermIncentivePlanAwardsAndDeferredShareAwardMember 2021-12-31 0001492074 abcm:ExpedeonAcquisitionMember 2021-12-31 0001492074 abcm:MarkerGeneTechnologiesIncAcquisitionMember 2021-12-31 0001492074 abcm:GeneEditingAndOncologyBusinessAcquisitionMember 2021-12-31 0001492074 abcm:ProvisionalFairValueMember abcm:GeneEditingAndOncologyBusinessAcquisitionMember 2021-12-31 0001492074 abcm:FairValueAdjustmentMember abcm:GeneEditingAndOncologyBusinessAcquisitionMember 2021-12-31 0001492074 ifrs-full:AtFairValueMember abcm:GeneEditingAndOncologyBusinessAcquisitionMember 2021-12-31 0001492074 abcm:IntangibleAssetsMember 2021-12-31 0001492074 abcm:AmountIncludedInSoftwareWithRemainderShownAsSoftwareAssetsUnderConstructionMember ifrs-full:ComputerSoftwareMember 2021-12-31 0001492074 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember 2021-12-31 0001492074 ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember 2021-12-31 0001492074 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember 2021-12-31 0001492074 ifrs-full:DerivativesMember 2021-12-31 0001492074 ifrs-full:DerivativesMember ifrs-full:Level2OfFairValueHierarchyMember 2021-12-31 0001492074 ifrs-full:OtherEquitySecuritiesMember 2021-12-31 0001492074 ifrs-full:OtherEquitySecuritiesMember ifrs-full:Level3OfFairValueHierarchyMember 2021-12-31 0001492074 ifrs-full:OtherEquitySecuritiesMember ifrs-full:Level2OfFairValueHierarchyMember 2021-12-31 0001492074 ifrs-full:OtherEquitySecuritiesMember ifrs-full:Level1OfFairValueHierarchyMember 2021-12-31 0001492074 ifrs-full:Level3OfFairValueHierarchyMember 2021-12-31 0001492074 ifrs-full:Level2OfFairValueHierarchyMember 2021-12-31 0001492074 ifrs-full:Level1OfFairValueHierarchyMember 2021-12-31 0001492074 currency:EUR abcm:SellOpenCurrencyForwardContractsMember 2021-12-31 0001492074 currency:JPY ifrs-full:NotLaterThanThreeMonthsMember abcm:SellOpenCurrencyForwardContractsMember 2021-12-31 0001492074 currency:JPY ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember abcm:SellOpenCurrencyForwardContractsMember 2021-12-31 0001492074 currency:JPY ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember abcm:SellOpenCurrencyForwardContractsMember 2021-12-31 0001492074 currency:JPY abcm:SellOpenCurrencyForwardContractsMember 2021-12-31 0001492074 ifrs-full:NotLaterThanThreeMonthsMember currency:CNY abcm:SellOpenCurrencyForwardContractsMember 2021-12-31 0001492074 ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember currency:CNY abcm:SellOpenCurrencyForwardContractsMember 2021-12-31 0001492074 currency:CNY abcm:SellOpenCurrencyForwardContractsMember 2021-12-31 0001492074 ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember currency:CNY abcm:SellOpenCurrencyForwardContractsMember 2021-12-31 0001492074 currency:EUR ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember abcm:SellOpenCurrencyForwardContractsMember 2021-12-31 0001492074 currency:EUR ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember abcm:SellOpenCurrencyForwardContractsMember 2021-12-31 0001492074 currency:EUR ifrs-full:NotLaterThanThreeMonthsMember abcm:SellOpenCurrencyForwardContractsMember 2021-12-31 0001492074 currency:USD abcm:SellOpenCurrencyForwardContractsMember 2021-12-31 0001492074 currency:USD ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember abcm:SellOpenCurrencyForwardContractsMember 2021-12-31 0001492074 ifrs-full:CashFlowHedgesMember 2021-12-31 0001492074 ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember 2021-12-31 0001492074 abcm:LaboratoryEquipmentMember 2021-12-31 0001492074 abcm:OfficeFixturesFittingsAndOtherEquipmentMember 2021-12-31 0001492074 abcm:CellLineAssetsMember 2021-12-31 0001492074 ifrs-full:LeaseholdImprovementsMember 2021-12-31 0001492074 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember 2021-12-31 0001492074 abcm:RetirementBenefitSchemesMember 2020-12-31 0001492074 abcm:EquinitiSharePlanTrusteesLimitedMember 2020-12-31 0001492074 ifrs-full:JointControlOrSignificantInfluenceMember 2020-12-31 0001492074 ifrs-full:TopOfRangeMember ifrs-full:JointControlOrSignificantInfluenceMember 2020-12-31 0001492074 abcm:CashAndCashEquivalentsMember 2020-12-31 0001492074 ifrs-full:LeaseLiabilitiesMember 2020-12-31 0001492074 ifrs-full:ShorttermBorrowingsMember 2020-12-31 0001492074 ifrs-full:NotLaterThanOneYearMember 2020-12-31 0001492074 ifrs-full:LaterThanOneYearMember 2020-12-31 0001492074 abcm:LaterThenOneYearAndNotLaterThenFiveYearsMember 2020-12-31 0001492074 ifrs-full:LaterThanFiveYearsMember 2020-12-31 0001492074 abcm:RestOfAsiaPacificMember 2020-12-31 0001492074 country:JP 2020-12-31 0001492074 country:CN 2020-12-31 0001492074 abcm:EmeaMember 2020-12-31 0001492074 abcm:TheAmericasMember 2020-12-31 0001492074 ifrs-full:PreviouslyStatedMember 2020-12-31 0001492074 ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember 2020-12-31 0001492074 abcm:RestatedBalanceMember 2020-12-31 0001492074 ifrs-full:GrossCarryingAmountMember 2020-12-31 0001492074 abcm:OptionsMember 2020-12-31 0001492074 abcm:NotDesignatedAsHedgingInstrumentMember ifrs-full:AtFairValueMember 2020-12-31 0001492074 ifrs-full:ForwardContractMember abcm:DesignatedAsHedgingInstrumentMember 2020-12-31 0001492074 abcm:ThousandAndTwentyPMember 2020-12-31 0001492074 abcm:EightHundredAndFiftyOnePMember 2020-12-31 0001492074 abcm:FiveHundredAndNinetyEightPMember 2020-12-31 0001492074 abcm:HundredAndEightyPointEightyPToFourHundredAndSixtyFourPMember ifrs-full:TopOfRangeMember 2020-12-31 0001492074 abcm:HundredAndEightyPointEightyPToFourHundredAndSixtyFourPMember ifrs-full:BottomOfRangeMember 2020-12-31 0001492074 abcm:HundredAndEightyPointEightyPToFourHundredAndSixtyFourPMember 2020-12-31 0001492074 abcm:PastDueMember 2020-12-31 0001492074 abcm:LaterThanSixtyDaysMember abcm:PastDueMember 2020-12-31 0001492074 abcm:LaterThanSixtyDaysMember abcm:PastDueMember ifrs-full:GrossCarryingAmountMember 2020-12-31 0001492074 abcm:NotPastDueMember ifrs-full:GrossCarryingAmountMember 2020-12-31 0001492074 abcm:NotPastDueMember 2020-12-31 0001492074 abcm:NotLaterThanThirtyDaysMember abcm:PastDueMember ifrs-full:GrossCarryingAmountMember 2020-12-31 0001492074 abcm:NotLaterThanThirtyDaysMember abcm:PastDueMember 2020-12-31 0001492074 abcm:LaterThanThirtyDaysAndNotLaterThanSixtyDaysMember abcm:PastDueMember ifrs-full:GrossCarryingAmountMember 2020-12-31 0001492074 abcm:LaterThanThirtyDaysAndNotLaterThanSixtyDaysMember abcm:PastDueMember 2020-12-31 0001492074 abcm:PastDueMember ifrs-full:GrossCarryingAmountMember 2020-12-31 0001492074 abcm:ShareIncentivePlanAwardsMember abcm:FreeSharesMember 2020-12-31 0001492074 abcm:ShareIncentivePlanAwardsMember abcm:MatchingSharesMember 2020-12-31 0001492074 abcm:AbShareAwardsMember 2020-12-31 0001492074 abcm:LongTermIncentivePlanAwardsAndDeferredShareAwardMember 2020-12-31 0001492074 abcm:IntangibleAssetsMember 2020-12-31 0001492074 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember 2020-12-31 0001492074 ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember 2020-12-31 0001492074 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember 2020-12-31 0001492074 ifrs-full:DerivativesMember 2020-12-31 0001492074 ifrs-full:DerivativesMember ifrs-full:Level2OfFairValueHierarchyMember 2020-12-31 0001492074 ifrs-full:OtherEquitySecuritiesMember 2020-12-31 0001492074 ifrs-full:OtherEquitySecuritiesMember ifrs-full:Level3OfFairValueHierarchyMember 2020-12-31 0001492074 ifrs-full:OtherEquitySecuritiesMember ifrs-full:Level1OfFairValueHierarchyMember 2020-12-31 0001492074 ifrs-full:Level3OfFairValueHierarchyMember 2020-12-31 0001492074 ifrs-full:Level2OfFairValueHierarchyMember 2020-12-31 0001492074 ifrs-full:Level1OfFairValueHierarchyMember 2020-12-31 0001492074 currency:USD ifrs-full:NotLaterThanThreeMonthsMember abcm:SellOpenCurrencyForwardContractsMember 2020-12-31 0001492074 currency:EUR abcm:SellOpenCurrencyForwardContractsMember 2020-12-31 0001492074 currency:JPY ifrs-full:NotLaterThanThreeMonthsMember abcm:SellOpenCurrencyForwardContractsMember 2020-12-31 0001492074 currency:JPY ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember abcm:SellOpenCurrencyForwardContractsMember 2020-12-31 0001492074 currency:JPY ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember abcm:SellOpenCurrencyForwardContractsMember 2020-12-31 0001492074 currency:JPY ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember abcm:SellOpenCurrencyForwardContractsMember 2020-12-31 0001492074 currency:JPY abcm:SellOpenCurrencyForwardContractsMember 2020-12-31 0001492074 ifrs-full:NotLaterThanThreeMonthsMember currency:CNY abcm:SellOpenCurrencyForwardContractsMember 2020-12-31 0001492074 ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember currency:CNY abcm:SellOpenCurrencyForwardContractsMember 2020-12-31 0001492074 currency:CNY abcm:SellOpenCurrencyForwardContractsMember 2020-12-31 0001492074 ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember currency:CNY abcm:SellOpenCurrencyForwardContractsMember 2020-12-31 0001492074 currency:EUR ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember abcm:SellOpenCurrencyForwardContractsMember 2020-12-31 0001492074 currency:EUR ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember abcm:SellOpenCurrencyForwardContractsMember 2020-12-31 0001492074 currency:EUR ifrs-full:NotLaterThanThreeMonthsMember abcm:SellOpenCurrencyForwardContractsMember 2020-12-31 0001492074 currency:USD abcm:SellOpenCurrencyForwardContractsMember 2020-12-31 0001492074 currency:USD ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember abcm:SellOpenCurrencyForwardContractsMember 2020-12-31 0001492074 currency:USD ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember abcm:SellOpenCurrencyForwardContractsMember 2020-12-31 0001492074 ifrs-full:CashFlowHedgesMember 2020-12-31 0001492074 ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember 2020-12-31 0001492074 abcm:LaboratoryEquipmentMember 2020-12-31 0001492074 abcm:OfficeFixturesFittingsAndOtherEquipmentMember 2020-12-31 0001492074 abcm:CellLineAssetsMember 2020-12-31 0001492074 ifrs-full:LeaseholdImprovementsMember 2020-12-31 0001492074 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember 2020-12-31 0001492074 abcm:RevolvingCreditFacilityMember 2020-06-30 0001492074 abcm:RetirementBenefitSchemesMember 2020-06-30 0001492074 abcm:EquinitiSharePlanTrusteesLimitedMember 2020-06-30 0001492074 ifrs-full:JointControlOrSignificantInfluenceMember 2020-06-30 0001492074 ifrs-full:TopOfRangeMember ifrs-full:JointControlOrSignificantInfluenceMember 2020-06-30 0001492074 abcm:CashAndCashEquivalentsMember 2020-06-30 0001492074 ifrs-full:LeaseLiabilitiesMember 2020-06-30 0001492074 ifrs-full:ShorttermBorrowingsMember 2020-06-30 0001492074 ifrs-full:NotLaterThanOneYearMember 2020-06-30 0001492074 ifrs-full:LaterThanOneYearMember 2020-06-30 0001492074 abcm:LaterThenOneYearAndNotLaterThenFiveYearsMember 2020-06-30 0001492074 ifrs-full:LaterThanFiveYearsMember 2020-06-30 0001492074 abcm:TheAmericasMember 2020-06-30 0001492074 abcm:EmeaMember 2020-06-30 0001492074 country:CN 2020-06-30 0001492074 country:JP 2020-06-30 0001492074 abcm:RestOfAsiaPacificMember 2020-06-30 0001492074 ifrs-full:PreviouslyStatedMember 2020-06-30 0001492074 ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember 2020-06-30 0001492074 abcm:RestatedBalanceMember 2020-06-30 0001492074 ifrs-full:GrossCarryingAmountMember 2020-06-30 0001492074 abcm:OptionsMember 2020-06-30 0001492074 abcm:NotDesignatedAsHedgingInstrumentMember ifrs-full:AtFairValueMember 2020-06-30 0001492074 ifrs-full:ForwardContractMember abcm:DesignatedAsHedgingInstrumentMember 2020-06-30 0001492074 abcm:ThousandAndTwentyPMember 2020-06-30 0001492074 abcm:EightHundredAndFiftyOnePMember 2020-06-30 0001492074 abcm:FiveHundredAndNinetyEightPMember 2020-06-30 0001492074 abcm:HundredAndEightyPointEightyPToFourHundredAndSixtyFourPMember ifrs-full:TopOfRangeMember 2020-06-30 0001492074 abcm:HundredAndEightyPointEightyPToFourHundredAndSixtyFourPMember ifrs-full:BottomOfRangeMember 2020-06-30 0001492074 abcm:HundredAndEightyPointEightyPToFourHundredAndSixtyFourPMember 2020-06-30 0001492074 abcm:PastDueMember 2020-06-30 0001492074 abcm:LaterThanSixtyDaysMember abcm:PastDueMember 2020-06-30 0001492074 abcm:NotPastDueMember ifrs-full:GrossCarryingAmountMember 2020-06-30 0001492074 abcm:NotPastDueMember 2020-06-30 0001492074 abcm:NotLaterThanThirtyDaysMember abcm:PastDueMember ifrs-full:GrossCarryingAmountMember 2020-06-30 0001492074 abcm:NotLaterThanThirtyDaysMember abcm:PastDueMember 2020-06-30 0001492074 abcm:LaterThanThirtyDaysAndNotLaterThanSixtyDaysMember abcm:PastDueMember ifrs-full:GrossCarryingAmountMember 2020-06-30 0001492074 abcm:LaterThanThirtyDaysAndNotLaterThanSixtyDaysMember abcm:PastDueMember 2020-06-30 0001492074 abcm:LaterThanSixtyDaysMember abcm:PastDueMember ifrs-full:GrossCarryingAmountMember 2020-06-30 0001492074 abcm:PastDueMember ifrs-full:GrossCarryingAmountMember 2020-06-30 0001492074 abcm:ShareIncentivePlanAwardsMember abcm:FreeSharesMember 2020-06-30 0001492074 abcm:ShareIncentivePlanAwardsMember abcm:MatchingSharesMember 2020-06-30 0001492074 abcm:AbShareAwardsMember 2020-06-30 0001492074 abcm:LongTermIncentivePlanAwardsAndDeferredShareAwardMember 2020-06-30 0001492074 abcm:IntangibleAssetsMember 2020-06-30 0001492074 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember 2020-06-30 0001492074 ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember 2020-06-30 0001492074 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember 2020-06-30 0001492074 ifrs-full:OtherEquitySecuritiesMember 2020-06-30 0001492074 ifrs-full:OtherEquitySecuritiesMember ifrs-full:Level3OfFairValueHierarchyMember 2020-06-30 0001492074 ifrs-full:OtherEquitySecuritiesMember ifrs-full:Level1OfFairValueHierarchyMember 2020-06-30 0001492074 ifrs-full:Level3OfFairValueHierarchyMember 2020-06-30 0001492074 ifrs-full:Level1OfFairValueHierarchyMember 2020-06-30 0001492074 ifrs-full:DerivativesMember 2020-06-30 0001492074 ifrs-full:Level2OfFairValueHierarchyMember ifrs-full:DerivativesMember 2020-06-30 0001492074 ifrs-full:Level2OfFairValueHierarchyMember 2020-06-30 0001492074 currency:EUR abcm:SellOpenCurrencyForwardContractsMember 2020-06-30 0001492074 currency:JPY ifrs-full:NotLaterThanThreeMonthsMember abcm:SellOpenCurrencyForwardContractsMember 2020-06-30 0001492074 currency:JPY ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember abcm:SellOpenCurrencyForwardContractsMember 2020-06-30 0001492074 currency:JPY ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember abcm:SellOpenCurrencyForwardContractsMember 2020-06-30 0001492074 currency:JPY ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember abcm:SellOpenCurrencyForwardContractsMember 2020-06-30 0001492074 currency:JPY abcm:SellOpenCurrencyForwardContractsMember 2020-06-30 0001492074 ifrs-full:NotLaterThanThreeMonthsMember currency:CNY abcm:SellOpenCurrencyForwardContractsMember 2020-06-30 0001492074 ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember currency:CNY abcm:SellOpenCurrencyForwardContractsMember 2020-06-30 0001492074 currency:CNY abcm:SellOpenCurrencyForwardContractsMember 2020-06-30 0001492074 ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember currency:CNY abcm:SellOpenCurrencyForwardContractsMember 2020-06-30 0001492074 currency:EUR ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember abcm:SellOpenCurrencyForwardContractsMember 2020-06-30 0001492074 currency:EUR ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember abcm:SellOpenCurrencyForwardContractsMember 2020-06-30 0001492074 currency:EUR ifrs-full:NotLaterThanThreeMonthsMember abcm:SellOpenCurrencyForwardContractsMember 2020-06-30 0001492074 currency:USD abcm:SellOpenCurrencyForwardContractsMember 2020-06-30 0001492074 currency:USD ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember abcm:SellOpenCurrencyForwardContractsMember 2020-06-30 0001492074 currency:USD ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember abcm:SellOpenCurrencyForwardContractsMember 2020-06-30 0001492074 currency:USD ifrs-full:NotLaterThanThreeMonthsMember abcm:SellOpenCurrencyForwardContractsMember 2020-06-30 0001492074 ifrs-full:CashFlowHedgesMember 2020-06-30 0001492074 ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember 2020-06-30 0001492074 abcm:LaboratoryEquipmentMember 2020-06-30 0001492074 abcm:OfficeFixturesFittingsAndOtherEquipmentMember 2020-06-30 0001492074 abcm:CellLineAssetsMember 2020-06-30 0001492074 ifrs-full:LeaseholdImprovementsMember 2020-06-30 0001492074 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember 2020-06-30 0001492074 ifrs-full:RetainedEarningsMember 2021-01-01 2021-12-31 0001492074 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-01-01 2021-12-31 0001492074 ifrs-full:SharePremiumMember 2021-01-01 2021-12-31 0001492074 ifrs-full:TreasurySharesMember 2021-01-01 2021-12-31 0001492074 abcm:GroupAndParentCompanyMember 2021-01-01 2021-12-31 0001492074 abcm:SubsidiaryCompaniesPursuantToLegislationMember 2021-01-01 2021-12-31 0001492074 abcm:ServicesInRespectOfTheGroupUsListingMember 2021-01-01 2021-12-31 0001492074 abcm:OtherAuditRelatedAssuaranceServicesMember 2021-01-01 2021-12-31 0001492074 abcm:InterimReviewMember 2021-01-01 2021-12-31 0001492074 abcm:AttestationUnderS404OfSarbanesOxleyAct2002AndAuditOf20fFilingMember 2021-01-01 2021-12-31 0001492074 abcm:ManagementAdministrativeMarketingAndDistributionMember 2021-01-01 2021-12-31 0001492074 abcm:LaboratoryMember 2021-01-01 2021-12-31 0001492074 abcm:EffectFromOneAprilTwoThousandAndTwentyThreeMember 2021-01-01 2021-12-31 0001492074 ifrs-full:TopOfRangeMember 2021-01-01 2021-12-31 0001492074 ifrs-full:BottomOfRangeMember abcm:ErpSoftwareAssetsMember 2021-01-01 2021-12-31 0001492074 ifrs-full:TopOfRangeMember abcm:ErpSoftwareAssetsMember 2021-01-01 2021-12-31 0001492074 ifrs-full:BottomOfRangeMember ifrs-full:ComputerSoftwareMember abcm:BiovisionBusinessMember 2021-01-01 2021-12-31 0001492074 ifrs-full:TopOfRangeMember ifrs-full:ComputerSoftwareMember abcm:BiovisionBusinessMember 2021-01-01 2021-12-31 0001492074 abcm:CostAndCarryingAmountMember 2021-01-01 2021-12-31 0001492074 ifrs-full:BottomOfRangeMember 2021-01-01 2021-12-31 0001492074 abcm:DirectorsMember 2021-01-01 2021-12-31 0001492074 ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2021-01-01 2021-12-31 0001492074 abcm:ExpedeonCaptsureTechnologyMember 2021-01-01 2021-12-31 0001492074 abcm:ExpedeonAntibodyLabellingAndConjugationTechnologyMember 2021-01-01 2021-12-31 0001492074 abcm:EpitomicsRabMabTechnologyMember 2021-01-01 2021-12-31 0001492074 abcm:FireflyBioworksMultiplexAndAssayTechnologyMember 2021-01-01 2021-12-31 0001492074 abcm:RocheLicenceAgreementMember 2021-01-01 2021-12-31 0001492074 abcm:BioVisionMetabolismAssaysAndProteinsMember 2021-01-01 2021-12-31 0001492074 abcm:CashAndCashEquivalentsMember 2021-01-01 2021-12-31 0001492074 ifrs-full:LeaseLiabilitiesMember 2021-01-01 2021-12-31 0001492074 ifrs-full:ShorttermBorrowingsMember 2021-01-01 2021-12-31 0001492074 abcm:FinalDividendForTheYearEndedJuneThirtyTwoThousandEighteenMember 2021-01-01 2021-12-31 0001492074 abcm:InterimDividendForTheYearEndedJuneThirtyTwoThousandNineteenMember 2021-01-01 2021-12-31 0001492074 abcm:FinalDividendForTheYearEndedJuneThirtyTwoThousandNineteenMember 2021-01-01 2021-12-31 0001492074 abcm:InterimDividendForTheYearEndedJuneThirtyTwoThousandTwentyMember 2021-01-01 2021-12-31 0001492074 ifrs-full:JointControlOrSignificantInfluenceMember 2021-01-01 2021-12-31 0001492074 ifrs-full:TopOfRangeMember ifrs-full:JointControlOrSignificantInfluenceMember 2021-01-01 2021-12-31 0001492074 abcm:DeferredTaxLiabilitiesNetMember 2021-01-01 2021-12-31 0001492074 ifrs-full:OtherTemporaryDifferencesMember abcm:DeferredTaxLiabilitiesNetMember 2021-01-01 2021-12-31 0001492074 ifrs-full:UnusedTaxLossesMember abcm:DeferredTaxLiabilitiesNetMember 2021-01-01 2021-12-31 0001492074 abcm:AcquiredIntangibleAssetsMember abcm:DeferredTaxLiabilitiesNetMember 2021-01-01 2021-12-31 0001492074 abcm:ShareBasedPaymentsMember abcm:DeferredTaxLiabilitiesNetMember 2021-01-01 2021-12-31 0001492074 abcm:AcceleratedCapitalAllowancesMember abcm:DeferredTaxLiabilitiesNetMember 2021-01-01 2021-12-31 0001492074 abcm:CalicoBiolabsIncMember 2021-01-01 2021-12-31 0001492074 abcm:EpitomicsIncMember 2021-01-01 2021-12-31 0001492074 abcm:EpitomicsHoldingsIncMember 2021-01-01 2021-12-31 0001492074 abcm:ExpedeonHoldingsLimitedMember 2021-01-01 2021-12-31 0001492074 abcm:ExpedeonLimitedMember 2021-01-01 2021-12-31 0001492074 abcm:ExpedeonAsiaPteLimitedMember 2021-01-01 2021-12-31 0001492074 abcm:FireflyBioworksIncMember 2021-01-01 2021-12-31 0001492074 abcm:InnovaBiosciencesLimitedMember 2021-01-01 2021-12-31 0001492074 abcm:MarkerGeneTechnologiesIncMember 2021-01-01 2021-12-31 0001492074 abcm:MitosciencesIncMember 2021-01-01 2021-12-31 0001492074 abcm:NkyBiotechUsIncMember 2021-01-01 2021-12-31 0001492074 abcm:TgrBiosciencesPtyLimitedMember 2021-01-01 2021-12-31 0001492074 abcm:AxiomxIncMember 2021-01-01 2021-12-31 0001492074 abcm:BiovisionIncMember 2021-01-01 2021-12-31 0001492074 abcm:AbcamTradingShanghaiCoLimitedMember 2021-01-01 2021-12-31 0001492074 abcm:AbcamIncMember 2021-01-01 2021-12-31 0001492074 abcm:AbcamLlcMember 2021-01-01 2021-12-31 0001492074 abcm:AbcamUsLimitedMember 2021-01-01 2021-12-31 0001492074 abcm:AbcamKkMember 2021-01-01 2021-12-31 0001492074 abcm:AbcamHongKongLimitedMember 2021-01-01 2021-12-31 0001492074 abcm:AbcamTaiwanCompanyLimitedMember 2021-01-01 2021-12-31 0001492074 abcm:AbcamNetherlandsBvMember 2021-01-01 2021-12-31 0001492074 abcm:AbcamUsGroupHoldingsIncMember 2021-01-01 2021-12-31 0001492074 abcm:AbcamSingaporePteLimitedMember 2021-01-01 2021-12-31 0001492074 abcm:AbshareSharePlanLimitedMember 2021-01-01 2021-12-31 0001492074 abcm:AscentScientificLimitedMember 2021-01-01 2021-12-31 0001492074 abcm:AbcamHangzhouBiotechnologyCoLimitedMember 2021-01-01 2021-12-31 0001492074 abcm:AbcamAustraliaPtyLimitedMember 2021-01-01 2021-12-31 0001492074 abcm:BioVisionBusinessMember 2021-01-01 2021-12-31 0001492074 ifrs-full:ComputerSoftwareMember abcm:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0001492074 ifrs-full:ComputerSoftwareMember 2021-01-01 2021-12-31 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember 2021-01-01 2021-12-31 0001492074 abcm:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0001492074 abcm:ResearchAndDevelopmentExpensesMember 2021-01-01 2021-12-31 0001492074 abcm:ExceptionalItemsMember 2021-01-01 2021-12-31 0001492074 ifrs-full:LandAndBuildingsMember ifrs-full:GrossCarryingAmountMember 2021-01-01 2021-12-31 0001492074 ifrs-full:OtherAssetsMember ifrs-full:GrossCarryingAmountMember 2021-01-01 2021-12-31 0001492074 ifrs-full:GrossCarryingAmountMember 2021-01-01 2021-12-31 0001492074 ifrs-full:LandAndBuildingsMember abcm:AccumulatedAmortizationMember 2021-01-01 2021-12-31 0001492074 ifrs-full:OtherAssetsMember abcm:AccumulatedAmortizationMember 2021-01-01 2021-12-31 0001492074 abcm:AccumulatedAmortizationMember 2021-01-01 2021-12-31 0001492074 abcm:CalicoAcquisitionMember 2021-01-01 2021-12-31 0001492074 abcm:ExpedeonAcquisitionMember 2021-01-01 2021-12-31 0001492074 abcm:BioVisionAcquisitionMember 2021-01-01 2021-12-31 0001492074 abcm:GeneEditingAndOncologyBusinessAcquisitionMember 2021-01-01 2021-12-31 0001492074 abcm:MarkerGeneTechnologiesIncAcquisitionMember 2021-01-01 2021-12-31 0001492074 abcm:TheAmericasMember 2021-01-01 2021-12-31 0001492074 abcm:EmeaMember 2021-01-01 2021-12-31 0001492074 country:CN 2021-01-01 2021-12-31 0001492074 country:JP 2021-01-01 2021-12-31 0001492074 abcm:RestOfAsiaPacificMember 2021-01-01 2021-12-31 0001492074 abcm:CatalogueRevenueMember 2021-01-01 2021-12-31 0001492074 abcm:CustomsProductsAndServicesMember 2021-01-01 2021-12-31 0001492074 abcm:IvdMember 2021-01-01 2021-12-31 0001492074 abcm:RoyaltiesAndLicensesMember 2021-01-01 2021-12-31 0001492074 abcm:CustomProductsAndLicensingMember 2021-01-01 2021-12-31 0001492074 abcm:ProductsAndServiceMember abcm:CustomerMember 2021-01-01 2021-12-31 0001492074 abcm:CentralAsiaMember 2021-01-01 2021-12-31 0001492074 abcm:LaboratoryEquipmentMember ifrs-full:GrossCarryingAmountMember 2021-01-01 2021-12-31 0001492074 abcm:OfficeFixturesFittingsAndOtherEquipmentMember ifrs-full:GrossCarryingAmountMember 2021-01-01 2021-12-31 0001492074 abcm:CellLineAssetsMember ifrs-full:GrossCarryingAmountMember 2021-01-01 2021-12-31 0001492074 ifrs-full:LeaseholdImprovementsMember ifrs-full:GrossCarryingAmountMember 2021-01-01 2021-12-31 0001492074 abcm:LaboratoryEquipmentMember abcm:AccumulatedDepreciationMember 2021-01-01 2021-12-31 0001492074 abcm:OfficeFixturesFittingsAndOtherEquipmentMember abcm:AccumulatedDepreciationMember 2021-01-01 2021-12-31 0001492074 abcm:CellLineAssetsMember abcm:AccumulatedDepreciationMember 2021-01-01 2021-12-31 0001492074 ifrs-full:LeaseholdImprovementsMember abcm:AccumulatedDepreciationMember 2021-01-01 2021-12-31 0001492074 abcm:AccumulatedDepreciationMember 2021-01-01 2021-12-31 0001492074 abcm:ProfitableGrowthIncentivePlanAwardsMember 2021-01-01 2021-12-31 0001492074 abcm:ShareIncentivePlanAwardsMember 2021-01-01 2021-12-31 0001492074 abcm:AbShareAwardsMember 2021-01-01 2021-12-31 0001492074 ifrs-full:SellingGeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001492074 abcm:ThousandAndTwentyPMember 2021-01-01 2021-12-31 0001492074 abcm:EightHundredAndFiftyOnePMember 2021-01-01 2021-12-31 0001492074 abcm:FiveHundredAndNinetyEightPMember 2021-01-01 2021-12-31 0001492074 abcm:HundredAndEightyPointEightyPToFourHundredAndSixtyFourPMember 2021-01-01 2021-12-31 0001492074 abcm:LongTermIncentivePlanAwardsAndDeferredShareAwardMember 2021-01-01 2021-12-31 0001492074 abcm:ShareIncentivePlanAwardsMember abcm:FreeSharesMember 2021-01-01 2021-12-31 0001492074 abcm:ShareIncentivePlanAwardsMember abcm:MatchingSharesMember 2021-01-01 2021-12-31 0001492074 abcm:LongTermIncentivePlanAwardsMember abcm:TrancheOneMember abcm:OneDecemberTwoThousandAndTwentyOneMember 2021-01-01 2021-12-31 0001492074 abcm:LongTermIncentivePlanAwardsMember abcm:TrancheTwoMember abcm:OneDecemberTwoThousandAndTwentyOneMember 2021-01-01 2021-12-31 0001492074 abcm:DeferredShareAwardMember abcm:TwentySixOctoberTwoThousandAndTwentyOneMember 2021-01-01 2021-12-31 0001492074 abcm:ProfitableGrowthIncentivePlanAwardsMember abcm:FourteenJulyTwoThousandAndTwentyOneMember 2021-01-01 2021-12-31 0001492074 abcm:ProfitableGrowthIncentivePlanAwardsMember abcm:FourteenSeptemberTwoThousandAndTwentyOneMember 2021-01-01 2021-12-31 0001492074 abcm:PatentsAndLicensesMember ifrs-full:GrossCarryingAmountMember 2021-01-01 2021-12-31 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:GrossCarryingAmountMember ifrs-full:InternallyGeneratedMember 2021-01-01 2021-12-31 0001492074 ifrs-full:ComputerSoftwareMember ifrs-full:GrossCarryingAmountMember 2021-01-01 2021-12-31 0001492074 abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2021-01-01 2021-12-31 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2021-01-01 2021-12-31 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2021-01-01 2021-12-31 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2021-01-01 2021-12-31 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2021-01-01 2021-12-31 0001492074 abcm:PatentsAndLicensesMember abcm:AccumulatedAmortizationMember 2021-01-01 2021-12-31 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2021-01-01 2021-12-31 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2021-01-01 2021-12-31 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2021-01-01 2021-12-31 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2021-01-01 2021-12-31 0001492074 abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2021-01-01 2021-12-31 0001492074 ifrs-full:ComputerSoftwareMember abcm:AccumulatedAmortizationMember 2021-01-01 2021-12-31 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:InternallyGeneratedMember abcm:AccumulatedAmortizationMember 2021-01-01 2021-12-31 0001492074 abcm:ProfitableGrowthIncentivePlanPgipMember 2021-01-01 2021-12-31 0001492074 abcm:ShareOptionSchemeSosMember 2021-01-01 2021-12-31 0001492074 abcm:LongTermIncentivePlanAwardsMember 2021-01-01 2021-12-31 0001492074 abcm:DeferredShareAwardMember 2021-01-01 2021-12-31 0001492074 abcm:ProfitableGrowthIncentivePlanPgipMember abcm:TrancheThreeAfterEighteenMonthsMember 2021-01-01 2021-12-31 0001492074 abcm:ProfitableGrowthIncentivePlanPgipMember abcm:TrancheTwoAfterTwelveMonthsMember 2021-01-01 2021-12-31 0001492074 abcm:ProfitableGrowthIncentivePlanPgipMember abcm:TrancheOneAfterSixMonthsMember 2021-01-01 2021-12-31 0001492074 dei:BusinessContactMember 2021-01-01 2021-12-31 0001492074 ifrs-full:ComputerSoftwareMember ifrs-full:PreviouslyStatedMember ifrs-full:BottomOfRangeMember 2021-01-01 2021-12-31 0001492074 ifrs-full:ComputerSoftwareMember ifrs-full:PreviouslyStatedMember ifrs-full:TopOfRangeMember 2021-01-01 2021-12-31 0001492074 ifrs-full:ComputerSoftwareMember ifrs-full:BottomOfRangeMember 2021-01-01 2021-12-31 0001492074 ifrs-full:ComputerSoftwareMember ifrs-full:TopOfRangeMember 2021-01-01 2021-12-31 0001492074 ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember 2021-01-01 2021-12-31 0001492074 abcm:AverageAnnualReductionMember abcm:TwoThousandAndTwentyTwoToTwoThousandAndTwentySixMember ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember 2021-01-01 2021-12-31 0001492074 ifrs-full:CapitalisedDevelopmentExpenditureMember 2021-01-01 2021-12-31 0001492074 abcm:SellingGeneralAndAdministrativeExpensesMember ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:InternallyGeneratedMember 2021-01-01 2021-12-31 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:InternallyGeneratedMember abcm:ResearchAndDevelopmentExpensesMember 2021-01-01 2021-12-31 0001492074 abcm:TradeNamesMember ifrs-full:TopOfRangeMember abcm:AcquisitionIntangiblesAssetsMember 2021-01-01 2021-12-31 0001492074 abcm:TradeNamesMember ifrs-full:BottomOfRangeMember abcm:AcquisitionIntangiblesAssetsMember 2021-01-01 2021-12-31 0001492074 abcm:PatentedTechnologyAndKnowhowMember ifrs-full:TopOfRangeMember abcm:AcquisitionIntangiblesAssetsMember 2021-01-01 2021-12-31 0001492074 abcm:PatentedTechnologyAndKnowhowMember ifrs-full:BottomOfRangeMember abcm:AcquisitionIntangiblesAssetsMember 2021-01-01 2021-12-31 0001492074 abcm:CustomerRelationshipsAndDistributionRightsMember ifrs-full:TopOfRangeMember abcm:AcquisitionIntangiblesAssetsMember 2021-01-01 2021-12-31 0001492074 abcm:CustomerRelationshipsAndDistributionRightsMember ifrs-full:BottomOfRangeMember abcm:AcquisitionIntangiblesAssetsMember 2021-01-01 2021-12-31 0001492074 abcm:PatentsAndLicencesMember ifrs-full:TopOfRangeMember abcm:OthersIntangibleAssetsMember 2021-01-01 2021-12-31 0001492074 abcm:PatentsAndLicencesMember ifrs-full:BottomOfRangeMember abcm:OthersIntangibleAssetsMember 2021-01-01 2021-12-31 0001492074 abcm:InternallyDevelopedTechnologyMember ifrs-full:TopOfRangeMember abcm:OthersIntangibleAssetsMember 2021-01-01 2021-12-31 0001492074 abcm:InternallyDevelopedTechnologyMember ifrs-full:BottomOfRangeMember abcm:OthersIntangibleAssetsMember 2021-01-01 2021-12-31 0001492074 abcm:SoftwareMember ifrs-full:TopOfRangeMember abcm:OthersIntangibleAssetsMember 2021-01-01 2021-12-31 0001492074 abcm:SoftwareMember ifrs-full:BottomOfRangeMember abcm:OthersIntangibleAssetsMember 2021-01-01 2021-12-31 0001492074 abcm:UsdEuroJapaneseYenAndReminibiMember 2021-01-01 2021-12-31 0001492074 ifrs-full:OfficeEquipmentMember ifrs-full:TopOfRangeMember 2021-01-01 2021-12-31 0001492074 ifrs-full:OfficeEquipmentMember ifrs-full:BottomOfRangeMember 2021-01-01 2021-12-31 0001492074 abcm:CellLineAssetsMember 2021-01-01 2021-12-31 0001492074 abcm:LaboratoryEquipmentMember ifrs-full:TopOfRangeMember 2021-01-01 2021-12-31 0001492074 abcm:LaboratoryEquipmentMember ifrs-full:BottomOfRangeMember 2021-01-01 2021-12-31 0001492074 abcm:GbpMember 2021-01-01 2021-12-31 0001492074 abcm:AmountIncludedInSoftwareWithRemainderShownAsSoftwareAssetsUnderConstructionMember ifrs-full:ComputerSoftwareMember 2021-01-01 2021-12-31 0001492074 currency:USD 2021-01-01 2021-12-31 0001492074 currency:EUR 2021-01-01 2021-12-31 0001492074 currency:JPY 2021-01-01 2021-12-31 0001492074 currency:CNY 2021-01-01 2021-12-31 0001492074 abcm:BrickbioMember 2021-01-01 2021-12-31 0001492074 abcm:SomaserveMember 2021-01-01 2021-12-31 0001492074 abcm:AcquisitionIntangiblesAssetsMember 2021-01-01 2021-12-31 0001492074 abcm:OthersIntangibleAssetsMember 2021-01-01 2021-12-31 0001492074 abcm:LicenceFeesMember abcm:AcquisitionIntangiblesAssetsMember 2021-01-01 2021-12-31 0001492074 ifrs-full:LeaseholdImprovementsMember 2021-01-01 2021-12-31 0001492074 ifrs-full:RetainedEarningsMember 2020-07-01 2020-12-31 0001492074 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2020-07-01 2020-12-31 0001492074 ifrs-full:ReserveOfCashFlowHedgesMember 2020-07-01 2020-12-31 0001492074 ifrs-full:IssuedCapitalMember 2020-07-01 2020-12-31 0001492074 ifrs-full:SharePremiumMember 2020-07-01 2020-12-31 0001492074 ifrs-full:TreasurySharesMember 2020-07-01 2020-12-31 0001492074 abcm:GroupAndParentCompanyMember 2020-07-01 2020-12-31 0001492074 abcm:SubsidiaryCompaniesPursuantToLegislationMember 2020-07-01 2020-12-31 0001492074 abcm:ServicesInRespectOfTheGroupUsListingMember 2020-07-01 2020-12-31 0001492074 abcm:OtherAuditRelatedAssuaranceServicesMember 2020-07-01 2020-12-31 0001492074 abcm:InterimReviewMember 2020-07-01 2020-12-31 0001492074 abcm:AttestationUnderS404OfSarbanesOxleyAct2002AndAuditOf20fFilingMember 2020-07-01 2020-12-31 0001492074 abcm:ManagementAdministrativeMarketingAndDistributionMember 2020-07-01 2020-12-31 0001492074 abcm:LaboratoryMember 2020-07-01 2020-12-31 0001492074 abcm:CostAndCarryingAmountMember 2020-07-01 2020-12-31 0001492074 abcm:DirectorsMember 2020-07-01 2020-12-31 0001492074 ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2020-07-01 2020-12-31 0001492074 abcm:CashAndCashEquivalentsMember 2020-07-01 2020-12-31 0001492074 ifrs-full:LeaseLiabilitiesMember 2020-07-01 2020-12-31 0001492074 ifrs-full:ShorttermBorrowingsMember 2020-07-01 2020-12-31 0001492074 abcm:FinalDividendForTheYearEndedJuneThirtyTwoThousandEighteenMember 2020-07-01 2020-12-31 0001492074 abcm:InterimDividendForTheYearEndedJuneThirtyTwoThousandNineteenMember 2020-07-01 2020-12-31 0001492074 abcm:FinalDividendForTheYearEndedJuneThirtyTwoThousandNineteenMember 2020-07-01 2020-12-31 0001492074 abcm:InterimDividendForTheYearEndedJuneThirtyTwoThousandTwentyMember 2020-07-01 2020-12-31 0001492074 ifrs-full:JointControlOrSignificantInfluenceMember 2020-07-01 2020-12-31 0001492074 ifrs-full:TopOfRangeMember ifrs-full:JointControlOrSignificantInfluenceMember 2020-07-01 2020-12-31 0001492074 abcm:AcceleratedCapitalAllowancesMember abcm:DeferredTaxLiabilitiesNetMember 2020-07-01 2020-12-31 0001492074 abcm:ShareBasedPaymentsMember abcm:DeferredTaxLiabilitiesNetMember 2020-07-01 2020-12-31 0001492074 abcm:AcquiredIntangibleAssetsMember abcm:DeferredTaxLiabilitiesNetMember 2020-07-01 2020-12-31 0001492074 abcm:DeferredTaxLiabilitiesNetMember 2020-07-01 2020-12-31 0001492074 ifrs-full:OtherTemporaryDifferencesMember abcm:DeferredTaxLiabilitiesNetMember 2020-07-01 2020-12-31 0001492074 ifrs-full:CashFlowHedgesMember abcm:DeferredTaxLiabilitiesNetMember 2020-07-01 2020-12-31 0001492074 ifrs-full:UnusedTaxLossesMember abcm:DeferredTaxLiabilitiesNetMember 2020-07-01 2020-12-31 0001492074 abcm:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2020-12-31 0001492074 abcm:BioVisionBusinessMember 2020-07-01 2020-12-31 0001492074 abcm:ResearchAndDevelopmentExpensesMember 2020-07-01 2020-12-31 0001492074 ifrs-full:LandAndBuildingsMember ifrs-full:GrossCarryingAmountMember 2020-07-01 2020-12-31 0001492074 ifrs-full:OtherAssetsMember ifrs-full:GrossCarryingAmountMember 2020-07-01 2020-12-31 0001492074 ifrs-full:GrossCarryingAmountMember 2020-07-01 2020-12-31 0001492074 ifrs-full:LandAndBuildingsMember abcm:AccumulatedAmortizationMember 2020-07-01 2020-12-31 0001492074 ifrs-full:OtherAssetsMember abcm:AccumulatedAmortizationMember 2020-07-01 2020-12-31 0001492074 abcm:AccumulatedAmortizationMember 2020-07-01 2020-12-31 0001492074 abcm:TheAmericasMember 2020-07-01 2020-12-31 0001492074 abcm:EmeaMember 2020-07-01 2020-12-31 0001492074 country:CN 2020-07-01 2020-12-31 0001492074 country:JP 2020-07-01 2020-12-31 0001492074 abcm:RestOfAsiaPacificMember 2020-07-01 2020-12-31 0001492074 abcm:CatalogueRevenueMember 2020-07-01 2020-12-31 0001492074 abcm:CustomsProductsAndServicesMember 2020-07-01 2020-12-31 0001492074 abcm:IvdMember 2020-07-01 2020-12-31 0001492074 abcm:RoyaltiesAndLicensesMember 2020-07-01 2020-12-31 0001492074 abcm:CustomProductsAndLicensingMember 2020-07-01 2020-12-31 0001492074 abcm:CentralAsiaMember 2020-07-01 2020-12-31 0001492074 abcm:LaboratoryEquipmentMember ifrs-full:GrossCarryingAmountMember 2020-07-01 2020-12-31 0001492074 abcm:OfficeFixturesFittingsAndOtherEquipmentMember ifrs-full:GrossCarryingAmountMember 2020-07-01 2020-12-31 0001492074 abcm:CellLineAssetsMember ifrs-full:GrossCarryingAmountMember 2020-07-01 2020-12-31 0001492074 ifrs-full:LeaseholdImprovementsMember ifrs-full:GrossCarryingAmountMember 2020-07-01 2020-12-31 0001492074 abcm:LaboratoryEquipmentMember abcm:AccumulatedDepreciationMember 2020-07-01 2020-12-31 0001492074 abcm:OfficeFixturesFittingsAndOtherEquipmentMember abcm:AccumulatedDepreciationMember 2020-07-01 2020-12-31 0001492074 abcm:CellLineAssetsMember abcm:AccumulatedDepreciationMember 2020-07-01 2020-12-31 0001492074 ifrs-full:LeaseholdImprovementsMember abcm:AccumulatedDepreciationMember 2020-07-01 2020-12-31 0001492074 abcm:AccumulatedDepreciationMember 2020-07-01 2020-12-31 0001492074 ifrs-full:PreviouslyStatedMember 2020-07-01 2020-12-31 0001492074 ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember 2020-07-01 2020-12-31 0001492074 abcm:RestatedBalanceMember 2020-07-01 2020-12-31 0001492074 ifrs-full:SellingGeneralAndAdministrativeExpenseMember 2020-07-01 2020-12-31 0001492074 abcm:ThousandAndTwentyPMember 2020-07-01 2020-12-31 0001492074 abcm:EightHundredAndFiftyOnePMember 2020-07-01 2020-12-31 0001492074 abcm:FiveHundredAndNinetyEightPMember 2020-07-01 2020-12-31 0001492074 abcm:HundredAndEightyPointEightyPToFourHundredAndSixtyFourPMember 2020-07-01 2020-12-31 0001492074 abcm:LongTermIncentivePlanAwardsAndDeferredShareAwardMember 2020-07-01 2020-12-31 0001492074 abcm:AbShareAwardsMember 2020-07-01 2020-12-31 0001492074 abcm:ShareIncentivePlanAwardsMember abcm:FreeSharesMember 2020-07-01 2020-12-31 0001492074 abcm:ShareIncentivePlanAwardsMember abcm:MatchingSharesMember 2020-07-01 2020-12-31 0001492074 abcm:LongTermIncentivePlanAwardsMember abcm:TrancheOneMember abcm:SevenDecemberTwoThousandAndTwentyMember 2020-07-01 2020-12-31 0001492074 abcm:LongTermIncentivePlanAwardsMember abcm:TrancheTwoMember abcm:SevenDecemberTwoThousandAndTwentyMember 2020-07-01 2020-12-31 0001492074 abcm:DeferredShareAwardMember abcm:TwentySixOctoberTwoThousandAndTwentyMember 2020-07-01 2020-12-31 0001492074 abcm:PatentsAndLicensesMember ifrs-full:GrossCarryingAmountMember 2020-07-01 2020-12-31 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:GrossCarryingAmountMember ifrs-full:InternallyGeneratedMember 2020-07-01 2020-12-31 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2020-07-01 2020-12-31 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2020-07-01 2020-12-31 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2020-07-01 2020-12-31 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2020-07-01 2020-12-31 0001492074 abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2020-07-01 2020-12-31 0001492074 ifrs-full:ComputerSoftwareMember ifrs-full:GrossCarryingAmountMember 2020-07-01 2020-12-31 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2020-07-01 2020-12-31 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2020-07-01 2020-12-31 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2020-07-01 2020-12-31 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2020-07-01 2020-12-31 0001492074 abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2020-07-01 2020-12-31 0001492074 ifrs-full:ComputerSoftwareMember abcm:AccumulatedAmortizationMember 2020-07-01 2020-12-31 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:InternallyGeneratedMember abcm:AccumulatedAmortizationMember 2020-07-01 2020-12-31 0001492074 abcm:PatentsAndLicensesMember abcm:AccumulatedAmortizationMember 2020-07-01 2020-12-31 0001492074 abcm:ShareOptionSchemeSosMember 2020-07-01 2020-12-31 0001492074 abcm:AcquisitionIntangiblesMember 2020-07-01 2020-12-31 0001492074 abcm:ExpedeonAcquisitionMember 2020-01-01 2020-06-30 0001492074 currency:USD 2020-01-01 2020-06-30 0001492074 currency:EUR 2020-01-01 2020-06-30 0001492074 currency:JPY 2020-01-01 2020-06-30 0001492074 currency:CNY 2020-01-01 2020-06-30 0001492074 currency:USD 2019-01-01 2019-06-30 0001492074 currency:EUR 2019-01-01 2019-06-30 0001492074 currency:JPY 2019-01-01 2019-06-30 0001492074 currency:CNY 2019-01-01 2019-06-30 0001492074 abcm:FinalDividendForTheYearEndedJuneThirtyTwoThousandNineteenMember 2019-01-01 2019-06-30 0001492074 abcm:RetirementBenefitSchemesMember 2019-06-30 0001492074 abcm:EquinitiSharePlanTrusteesLimitedMember 2019-06-30 0001492074 ifrs-full:TopOfRangeMember ifrs-full:JointControlOrSignificantInfluenceMember 2019-06-30 0001492074 abcm:CashAndCashEquivalentsMember 2019-06-30 0001492074 ifrs-full:LeaseLiabilitiesMember 2019-06-30 0001492074 ifrs-full:ShorttermBorrowingsMember 2019-06-30 0001492074 ifrs-full:NotLaterThanOneYearMember 2019-06-30 0001492074 ifrs-full:LaterThanOneYearMember 2019-06-30 0001492074 abcm:TheAmericasMember 2019-06-30 0001492074 abcm:EmeaMember 2019-06-30 0001492074 country:CN 2019-06-30 0001492074 country:JP 2019-06-30 0001492074 abcm:RestOfAsiaPacificMember 2019-06-30 0001492074 ifrs-full:PreviouslyStatedMember 2019-06-30 0001492074 ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember 2019-06-30 0001492074 abcm:RestatedBalanceMember 2019-06-30 0001492074 ifrs-full:GrossCarryingAmountMember 2019-06-30 0001492074 abcm:OptionsMember 2019-06-30 0001492074 abcm:DesignatedAsHedgingInstrumentMember ifrs-full:ForwardContractMember 2019-06-30 0001492074 ifrs-full:AtFairValueMember abcm:NotDesignatedAsHedgingInstrumentMember 2019-06-30 0001492074 abcm:ThousandAndTwentyPMember 2019-06-30 0001492074 abcm:EightHundredAndFiftyOnePMember 2019-06-30 0001492074 abcm:FiveHundredAndNinetyEightPMember 2019-06-30 0001492074 abcm:HundredAndEightyPointEightyPToFourHundredAndSixtyFourPMember ifrs-full:TopOfRangeMember 2019-06-30 0001492074 abcm:HundredAndEightyPointEightyPToFourHundredAndSixtyFourPMember ifrs-full:BottomOfRangeMember 2019-06-30 0001492074 abcm:HundredAndEightyPointEightyPToFourHundredAndSixtyFourPMember 2019-06-30 0001492074 abcm:PastDueMember 2019-06-30 0001492074 abcm:LaterThanSixtyDaysMember abcm:PastDueMember 2019-06-30 0001492074 abcm:NotPastDueMember ifrs-full:GrossCarryingAmountMember 2019-06-30 0001492074 abcm:NotPastDueMember 2019-06-30 0001492074 abcm:NotLaterThanThirtyDaysMember abcm:PastDueMember ifrs-full:GrossCarryingAmountMember 2019-06-30 0001492074 abcm:NotLaterThanThirtyDaysMember abcm:PastDueMember 2019-06-30 0001492074 abcm:LaterThanThirtyDaysAndNotLaterThanSixtyDaysMember abcm:PastDueMember ifrs-full:GrossCarryingAmountMember 2019-06-30 0001492074 abcm:LaterThanThirtyDaysAndNotLaterThanSixtyDaysMember abcm:PastDueMember 2019-06-30 0001492074 abcm:LaterThanSixtyDaysMember abcm:PastDueMember ifrs-full:GrossCarryingAmountMember 2019-06-30 0001492074 abcm:PastDueMember ifrs-full:GrossCarryingAmountMember 2019-06-30 0001492074 abcm:ShareIncentivePlanAwardsMember abcm:FreeSharesMember 2019-06-30 0001492074 abcm:ShareIncentivePlanAwardsMember abcm:MatchingSharesMember 2019-06-30 0001492074 abcm:AbShareAwardsMember 2019-06-30 0001492074 abcm:LongTermIncentivePlanAwardsAndDeferredShareAwardMember 2019-06-30 0001492074 abcm:IntangibleAssetsMember 2019-06-30 0001492074 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember 2019-06-30 0001492074 ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember 2019-06-30 0001492074 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember 2019-06-30 0001492074 ifrs-full:DerivativesMember 2019-06-30 0001492074 ifrs-full:DerivativesMember ifrs-full:Level2OfFairValueHierarchyMember 2019-06-30 0001492074 ifrs-full:OtherEquitySecuritiesMember 2019-06-30 0001492074 ifrs-full:OtherEquitySecuritiesMember ifrs-full:Level1OfFairValueHierarchyMember 2019-06-30 0001492074 ifrs-full:Level2OfFairValueHierarchyMember 2019-06-30 0001492074 ifrs-full:Level1OfFairValueHierarchyMember 2019-06-30 0001492074 currency:EUR ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember abcm:SellOpenCurrencyForwardContractsMember 2019-06-30 0001492074 currency:EUR abcm:SellOpenCurrencyForwardContractsMember 2019-06-30 0001492074 currency:JPY ifrs-full:NotLaterThanThreeMonthsMember abcm:SellOpenCurrencyForwardContractsMember 2019-06-30 0001492074 currency:JPY ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember abcm:SellOpenCurrencyForwardContractsMember 2019-06-30 0001492074 currency:JPY ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember abcm:SellOpenCurrencyForwardContractsMember 2019-06-30 0001492074 currency:JPY ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember abcm:SellOpenCurrencyForwardContractsMember 2019-06-30 0001492074 currency:JPY abcm:SellOpenCurrencyForwardContractsMember 2019-06-30 0001492074 ifrs-full:NotLaterThanThreeMonthsMember currency:CNY abcm:SellOpenCurrencyForwardContractsMember 2019-06-30 0001492074 ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember currency:CNY abcm:SellOpenCurrencyForwardContractsMember 2019-06-30 0001492074 ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember currency:CNY abcm:SellOpenCurrencyForwardContractsMember 2019-06-30 0001492074 currency:CNY abcm:SellOpenCurrencyForwardContractsMember 2019-06-30 0001492074 currency:EUR ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember abcm:SellOpenCurrencyForwardContractsMember 2019-06-30 0001492074 currency:EUR ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember abcm:SellOpenCurrencyForwardContractsMember 2019-06-30 0001492074 currency:EUR ifrs-full:NotLaterThanThreeMonthsMember abcm:SellOpenCurrencyForwardContractsMember 2019-06-30 0001492074 currency:USD abcm:SellOpenCurrencyForwardContractsMember 2019-06-30 0001492074 currency:USD ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember abcm:SellOpenCurrencyForwardContractsMember 2019-06-30 0001492074 currency:USD ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember abcm:SellOpenCurrencyForwardContractsMember 2019-06-30 0001492074 currency:USD ifrs-full:NotLaterThanThreeMonthsMember abcm:SellOpenCurrencyForwardContractsMember 2019-06-30 0001492074 ifrs-full:CashFlowHedgesMember 2019-06-30 0001492074 ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember 2019-06-30 0001492074 abcm:LaboratoryEquipmentMember 2019-06-30 0001492074 abcm:OfficeFixturesFittingsAndOtherEquipmentMember 2019-06-30 0001492074 abcm:CellLineAssetsMember 2019-06-30 0001492074 ifrs-full:LeaseholdImprovementsMember 2019-06-30 0001492074 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember 2019-06-30 0001492074 ifrs-full:RetainedEarningsMember 2018-07-01 2019-06-30 0001492074 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2018-07-01 2019-06-30 0001492074 ifrs-full:ReserveOfCashFlowHedgesMember 2018-07-01 2019-06-30 0001492074 ifrs-full:SharePremiumMember 2018-07-01 2019-06-30 0001492074 ifrs-full:TreasurySharesMember 2018-07-01 2019-06-30 0001492074 abcm:GroupAndParentCompanyMember 2018-07-01 2019-06-30 0001492074 abcm:SubsidiaryCompaniesPursuantToLegislationMember 2018-07-01 2019-06-30 0001492074 abcm:ServicesInRespectOfTheGroupUsListingMember 2018-07-01 2019-06-30 0001492074 abcm:OtherAuditRelatedAssuaranceServicesMember 2018-07-01 2019-06-30 0001492074 abcm:InterimReviewMember 2018-07-01 2019-06-30 0001492074 abcm:AttestationUnderS404OfSarbanesOxleyAct2002AndAuditOf20fFilingMember 2018-07-01 2019-06-30 0001492074 abcm:ManagementAdministrativeMarketingAndDistributionMember 2018-07-01 2019-06-30 0001492074 abcm:LaboratoryMember 2018-07-01 2019-06-30 0001492074 abcm:CostAndCarryingAmountMember 2018-07-01 2019-06-30 0001492074 abcm:DirectorsMember 2018-07-01 2019-06-30 0001492074 ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2018-07-01 2019-06-30 0001492074 abcm:CashAndCashEquivalentsMember 2018-07-01 2019-06-30 0001492074 ifrs-full:LeaseLiabilitiesMember 2018-07-01 2019-06-30 0001492074 ifrs-full:ShorttermBorrowingsMember 2018-07-01 2019-06-30 0001492074 abcm:FinalDividendForTheYearEndedJuneThirtyTwoThousandEighteenMember 2018-07-01 2019-06-30 0001492074 abcm:InterimDividendForTheYearEndedJuneThirtyTwoThousandNineteenMember 2018-07-01 2019-06-30 0001492074 ifrs-full:JointControlOrSignificantInfluenceMember ifrs-full:TopOfRangeMember 2018-07-01 2019-06-30 0001492074 abcm:DeferredTaxLiabilitiesNetMember 2018-07-01 2019-06-30 0001492074 ifrs-full:OtherTemporaryDifferencesMember abcm:DeferredTaxLiabilitiesNetMember 2018-07-01 2019-06-30 0001492074 ifrs-full:UnusedTaxLossesMember abcm:DeferredTaxLiabilitiesNetMember 2018-07-01 2019-06-30 0001492074 abcm:AcquiredIntangibleAssetsMember abcm:DeferredTaxLiabilitiesNetMember 2018-07-01 2019-06-30 0001492074 abcm:ShareBasedPaymentsMember abcm:DeferredTaxLiabilitiesNetMember 2018-07-01 2019-06-30 0001492074 abcm:AcceleratedCapitalAllowancesMember abcm:DeferredTaxLiabilitiesNetMember 2018-07-01 2019-06-30 0001492074 ifrs-full:CashFlowHedgesMember abcm:DeferredTaxLiabilitiesNetMember 2018-07-01 2019-06-30 0001492074 abcm:SellingGeneralAndAdministrativeExpensesMember 2018-07-01 2019-06-30 0001492074 abcm:ResearchAndDevelopmentExpensesMember 2018-07-01 2019-06-30 0001492074 abcm:TheAmericasMember 2018-07-01 2019-06-30 0001492074 abcm:EmeaMember 2018-07-01 2019-06-30 0001492074 country:CN 2018-07-01 2019-06-30 0001492074 country:JP 2018-07-01 2019-06-30 0001492074 abcm:RestOfAsiaPacificMember 2018-07-01 2019-06-30 0001492074 abcm:CatalogueRevenueMember 2018-07-01 2019-06-30 0001492074 abcm:CustomsProductsAndServicesMember 2018-07-01 2019-06-30 0001492074 abcm:IvdMember 2018-07-01 2019-06-30 0001492074 abcm:RoyaltiesAndLicensesMember 2018-07-01 2019-06-30 0001492074 abcm:CustomProductsAndLicensingMember 2018-07-01 2019-06-30 0001492074 abcm:CentralAsiaMember 2018-07-01 2019-06-30 0001492074 abcm:LaboratoryEquipmentMember ifrs-full:GrossCarryingAmountMember 2018-07-01 2019-06-30 0001492074 abcm:OfficeFixturesFittingsAndOtherEquipmentMember ifrs-full:GrossCarryingAmountMember 2018-07-01 2019-06-30 0001492074 abcm:CellLineAssetsMember ifrs-full:GrossCarryingAmountMember 2018-07-01 2019-06-30 0001492074 ifrs-full:LeaseholdImprovementsMember ifrs-full:GrossCarryingAmountMember 2018-07-01 2019-06-30 0001492074 ifrs-full:GrossCarryingAmountMember 2018-07-01 2019-06-30 0001492074 abcm:LaboratoryEquipmentMember abcm:AccumulatedDepreciationMember 2018-07-01 2019-06-30 0001492074 abcm:OfficeFixturesFittingsAndOtherEquipmentMember abcm:AccumulatedDepreciationMember 2018-07-01 2019-06-30 0001492074 abcm:CellLineAssetsMember abcm:AccumulatedDepreciationMember 2018-07-01 2019-06-30 0001492074 ifrs-full:LeaseholdImprovementsMember abcm:AccumulatedDepreciationMember 2018-07-01 2019-06-30 0001492074 abcm:AccumulatedDepreciationMember 2018-07-01 2019-06-30 0001492074 ifrs-full:PreviouslyStatedMember 2018-07-01 2019-06-30 0001492074 ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember 2018-07-01 2019-06-30 0001492074 abcm:RestatedBalanceMember 2018-07-01 2019-06-30 0001492074 ifrs-full:SellingGeneralAndAdministrativeExpenseMember 2018-07-01 2019-06-30 0001492074 abcm:ThousandAndTwentyPMember 2018-07-01 2019-06-30 0001492074 abcm:EightHundredAndFiftyOnePMember 2018-07-01 2019-06-30 0001492074 abcm:FiveHundredAndNinetyEightPMember 2018-07-01 2019-06-30 0001492074 abcm:HundredAndEightyPointEightyPToFourHundredAndSixtyFourPMember 2018-07-01 2019-06-30 0001492074 abcm:LongTermIncentivePlanAwardsAndDeferredShareAwardMember 2018-07-01 2019-06-30 0001492074 abcm:AbShareAwardsMember 2018-07-01 2019-06-30 0001492074 abcm:ShareIncentivePlanAwardsMember abcm:FreeSharesMember 2018-07-01 2019-06-30 0001492074 abcm:ShareIncentivePlanAwardsMember abcm:MatchingSharesMember 2018-07-01 2019-06-30 0001492074 abcm:TwentySixOctoberTwoThousandAndEighteenMember abcm:DeferredShareAwardMember 2018-07-01 2019-06-30 0001492074 abcm:SevenNovemberTwoThousandAndEighteenMember abcm:LongTermIncentivePlanAwardsMember 2018-07-01 2019-06-30 0001492074 abcm:PatentsAndLicensesMember ifrs-full:GrossCarryingAmountMember 2018-07-01 2019-06-30 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:GrossCarryingAmountMember ifrs-full:InternallyGeneratedMember 2018-07-01 2019-06-30 0001492074 ifrs-full:ComputerSoftwareMember ifrs-full:GrossCarryingAmountMember 2018-07-01 2019-06-30 0001492074 abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2018-07-01 2019-06-30 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2018-07-01 2019-06-30 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2018-07-01 2019-06-30 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2018-07-01 2019-06-30 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2018-07-01 2019-06-30 0001492074 abcm:AccumulatedAmortizationMember 2018-07-01 2019-06-30 0001492074 abcm:PatentsAndLicensesMember abcm:AccumulatedAmortizationMember 2018-07-01 2019-06-30 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:InternallyGeneratedMember abcm:AccumulatedAmortizationMember 2018-07-01 2019-06-30 0001492074 ifrs-full:ComputerSoftwareMember abcm:AccumulatedAmortizationMember 2018-07-01 2019-06-30 0001492074 abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2018-07-01 2019-06-30 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2018-07-01 2019-06-30 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2018-07-01 2019-06-30 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2018-07-01 2019-06-30 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2018-07-01 2019-06-30 0001492074 abcm:ShareOptionSchemeSosMember 2018-07-01 2019-06-30 0001492074 ifrs-full:RetainedEarningsMember 2019-07-01 2020-06-30 0001492074 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2019-07-01 2020-06-30 0001492074 ifrs-full:ReserveOfCashFlowHedgesMember 2019-07-01 2020-06-30 0001492074 ifrs-full:SharePremiumMember 2019-07-01 2020-06-30 0001492074 ifrs-full:MergerReserveMember 2019-07-01 2020-06-30 0001492074 ifrs-full:TreasurySharesMember 2019-07-01 2020-06-30 0001492074 abcm:GroupAndParentCompanyMember 2019-07-01 2020-06-30 0001492074 abcm:SubsidiaryCompaniesPursuantToLegislationMember 2019-07-01 2020-06-30 0001492074 abcm:AssuranceServicesInRespectOfControlsWorkForUsComplianceMember 2019-07-01 2020-06-30 0001492074 abcm:ServicesInRespectOfTheGroupUsListingMember 2019-07-01 2020-06-30 0001492074 abcm:OtherAuditRelatedAssuaranceServicesMember 2019-07-01 2020-06-30 0001492074 abcm:InterimReviewMember 2019-07-01 2020-06-30 0001492074 abcm:AttestationUnderS404OfSarbanesOxleyAct2002AndAuditOf20fFilingMember 2019-07-01 2020-06-30 0001492074 abcm:ManagementAdministrativeMarketingAndDistributionMember 2019-07-01 2020-06-30 0001492074 abcm:LaboratoryMember 2019-07-01 2020-06-30 0001492074 abcm:RevolvingCreditFacilityMember 2019-07-01 2020-06-30 0001492074 abcm:CostAndCarryingAmountMember 2019-07-01 2020-06-30 0001492074 abcm:DirectorsMember 2019-07-01 2020-06-30 0001492074 ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2019-07-01 2020-06-30 0001492074 abcm:CashAndCashEquivalentsMember 2019-07-01 2020-06-30 0001492074 ifrs-full:LeaseLiabilitiesMember 2019-07-01 2020-06-30 0001492074 ifrs-full:ShorttermBorrowingsMember 2019-07-01 2020-06-30 0001492074 abcm:FinalDividendForTheYearEndedJuneThirtyTwoThousandNineteenMember 2019-07-01 2020-06-30 0001492074 abcm:InterimDividendForTheYearEndedJuneThirtyTwoThousandTwentyMember 2019-07-01 2020-06-30 0001492074 ifrs-full:JointControlOrSignificantInfluenceMember 2019-07-01 2020-06-30 0001492074 ifrs-full:TopOfRangeMember ifrs-full:JointControlOrSignificantInfluenceMember 2019-07-01 2020-06-30 0001492074 abcm:DeferredTaxLiabilitiesNetMember 2019-07-01 2020-06-30 0001492074 ifrs-full:OtherTemporaryDifferencesMember abcm:DeferredTaxLiabilitiesNetMember 2019-07-01 2020-06-30 0001492074 ifrs-full:UnusedTaxLossesMember abcm:DeferredTaxLiabilitiesNetMember 2019-07-01 2020-06-30 0001492074 abcm:AcquiredIntangibleAssetsMember abcm:DeferredTaxLiabilitiesNetMember 2019-07-01 2020-06-30 0001492074 abcm:ShareBasedPaymentsMember abcm:DeferredTaxLiabilitiesNetMember 2019-07-01 2020-06-30 0001492074 abcm:AcceleratedCapitalAllowancesMember abcm:DeferredTaxLiabilitiesNetMember 2019-07-01 2020-06-30 0001492074 ifrs-full:CashFlowHedgesMember abcm:DeferredTaxLiabilitiesNetMember 2019-07-01 2020-06-30 0001492074 abcm:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2020-06-30 0001492074 abcm:BioVisionBusinessMember 2019-07-01 2020-06-30 0001492074 abcm:ResearchAndDevelopmentExpensesMember 2019-07-01 2020-06-30 0001492074 ifrs-full:GrossCarryingAmountMember 2019-07-01 2020-06-30 0001492074 ifrs-full:LandAndBuildingsMember abcm:Ifrs16Member ifrs-full:GrossCarryingAmountMember 2019-07-01 2020-06-30 0001492074 ifrs-full:OtherAssetsMember abcm:Ifrs16Member ifrs-full:GrossCarryingAmountMember 2019-07-01 2020-06-30 0001492074 abcm:Ifrs16Member ifrs-full:GrossCarryingAmountMember 2019-07-01 2020-06-30 0001492074 ifrs-full:LandAndBuildingsMember ifrs-full:GrossCarryingAmountMember 2019-07-01 2020-06-30 0001492074 ifrs-full:OtherAssetsMember ifrs-full:GrossCarryingAmountMember 2019-07-01 2020-06-30 0001492074 ifrs-full:LandAndBuildingsMember abcm:AccumulatedAmortizationMember 2019-07-01 2020-06-30 0001492074 ifrs-full:OtherAssetsMember abcm:AccumulatedAmortizationMember 2019-07-01 2020-06-30 0001492074 abcm:AccumulatedAmortizationMember 2019-07-01 2020-06-30 0001492074 abcm:TheAmericasMember 2019-07-01 2020-06-30 0001492074 abcm:EmeaMember 2019-07-01 2020-06-30 0001492074 country:CN 2019-07-01 2020-06-30 0001492074 country:JP 2019-07-01 2020-06-30 0001492074 abcm:RestOfAsiaPacificMember 2019-07-01 2020-06-30 0001492074 abcm:CatalogueRevenueMember 2019-07-01 2020-06-30 0001492074 abcm:CustomsProductsAndServicesMember 2019-07-01 2020-06-30 0001492074 abcm:IvdMember 2019-07-01 2020-06-30 0001492074 abcm:RoyaltiesAndLicensesMember 2019-07-01 2020-06-30 0001492074 abcm:CustomProductsAndLicensingMember 2019-07-01 2020-06-30 0001492074 abcm:CentralAsiaMember 2019-07-01 2020-06-30 0001492074 abcm:LaboratoryEquipmentMember ifrs-full:GrossCarryingAmountMember 2019-07-01 2020-06-30 0001492074 abcm:OfficeFixturesFittingsAndOtherEquipmentMember ifrs-full:GrossCarryingAmountMember 2019-07-01 2020-06-30 0001492074 abcm:CellLineAssetsMember ifrs-full:GrossCarryingAmountMember 2019-07-01 2020-06-30 0001492074 ifrs-full:LeaseholdImprovementsMember ifrs-full:GrossCarryingAmountMember 2019-07-01 2020-06-30 0001492074 abcm:LaboratoryEquipmentMember abcm:AccumulatedDepreciationMember 2019-07-01 2020-06-30 0001492074 abcm:OfficeFixturesFittingsAndOtherEquipmentMember abcm:AccumulatedDepreciationMember 2019-07-01 2020-06-30 0001492074 abcm:CellLineAssetsMember abcm:AccumulatedDepreciationMember 2019-07-01 2020-06-30 0001492074 ifrs-full:LeaseholdImprovementsMember abcm:AccumulatedDepreciationMember 2019-07-01 2020-06-30 0001492074 abcm:AccumulatedDepreciationMember 2019-07-01 2020-06-30 0001492074 ifrs-full:PreviouslyStatedMember 2019-07-01 2020-06-30 0001492074 ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember 2019-07-01 2020-06-30 0001492074 abcm:RestatedBalanceMember 2019-07-01 2020-06-30 0001492074 ifrs-full:SellingGeneralAndAdministrativeExpenseMember 2019-07-01 2020-06-30 0001492074 abcm:ThousandAndTwentyPMember 2019-07-01 2020-06-30 0001492074 abcm:EightHundredAndFiftyOnePMember 2019-07-01 2020-06-30 0001492074 abcm:FiveHundredAndNinetyEightPMember 2019-07-01 2020-06-30 0001492074 abcm:HundredAndEightyPointEightyPToFourHundredAndSixtyFourPMember 2019-07-01 2020-06-30 0001492074 abcm:LongTermIncentivePlanAwardsAndDeferredShareAwardMember 2019-07-01 2020-06-30 0001492074 abcm:AbShareAwardsMember 2019-07-01 2020-06-30 0001492074 abcm:ShareIncentivePlanAwardsMember abcm:FreeSharesMember 2019-07-01 2020-06-30 0001492074 abcm:ShareIncentivePlanAwardsMember abcm:MatchingSharesMember 2019-07-01 2020-06-30 0001492074 abcm:LongTermIncentivePlanAwardsMember abcm:FourteenNovemberTwoThousandAndNineteenMember 2019-07-01 2020-06-30 0001492074 abcm:LongTermIncentivePlanAwardsMember abcm:NineMarchTwoThousandAndTwentyMember abcm:TrancheOneMember 2019-07-01 2020-06-30 0001492074 abcm:LongTermIncentivePlanAwardsMember abcm:NineMarchTwoThousandAndTwentyMember abcm:TrancheTwoMember 2019-07-01 2020-06-30 0001492074 abcm:LongTermIncentivePlanAwardsMember abcm:NineMarchTwoThousandAndTwentyMember abcm:TrancheThreeMember 2019-07-01 2020-06-30 0001492074 abcm:DeferredShareAwardMember abcm:TwentyFiveOctoberTwoThousandAndNineteenMember 2019-07-01 2020-06-30 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2019-07-01 2020-06-30 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2019-07-01 2020-06-30 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2019-07-01 2020-06-30 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2019-07-01 2020-06-30 0001492074 abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2019-07-01 2020-06-30 0001492074 ifrs-full:ComputerSoftwareMember ifrs-full:GrossCarryingAmountMember 2019-07-01 2020-06-30 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:GrossCarryingAmountMember ifrs-full:InternallyGeneratedMember 2019-07-01 2020-06-30 0001492074 abcm:PatentsAndLicensesMember ifrs-full:GrossCarryingAmountMember 2019-07-01 2020-06-30 0001492074 abcm:PatentsAndLicensesMember abcm:AccumulatedAmortizationMember 2019-07-01 2020-06-30 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:InternallyGeneratedMember abcm:AccumulatedAmortizationMember 2019-07-01 2020-06-30 0001492074 ifrs-full:ComputerSoftwareMember abcm:AccumulatedAmortizationMember 2019-07-01 2020-06-30 0001492074 abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2019-07-01 2020-06-30 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2019-07-01 2020-06-30 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2019-07-01 2020-06-30 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2019-07-01 2020-06-30 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2019-07-01 2020-06-30 0001492074 abcm:ShareOptionSchemeSosMember 2019-07-01 2020-06-30 0001492074 currency:USD 2020-01-01 2020-12-31 0001492074 currency:EUR 2020-01-01 2020-12-31 0001492074 currency:JPY 2020-01-01 2020-12-31 0001492074 currency:CNY 2020-01-01 2020-12-31 0001492074 abcm:RevolvingCreditFacilityMember 2019-02-01 2019-02-28 0001492074 abcm:RevolvingCreditFacilityMember 2020-03-01 2020-03-31 0001492074 abcm:RevolvingCreditFacilityMember 2020-11-23 2020-11-23 0001492074 abcm:RevolvingCreditFacilityMember abcm:BiovisionBusinessMember 2021-10-19 2021-10-19 0001492074 abcm:AmericanDepositarySharesMember 2020-10-26 0001492074 abcm:AmericanDepositarySharesMember 2020-10-26 2020-10-26 0001492074 ifrs-full:OrdinarySharesMember 2020-10-26 2020-10-26 0001492074 ifrs-full:OrdinarySharesMember abcm:DurablePartnersLpMember 2020-04-09 0001492074 ifrs-full:OrdinarySharesMember abcm:DurablePartnersLpMember 2020-04-09 2020-04-09 0001492074 abcm:CashAndCashEquivalentsMember 2018-07-01 0001492074 ifrs-full:LeaseLiabilitiesMember 2018-07-01 0001492074 ifrs-full:ShorttermBorrowingsMember 2018-07-01 0001492074 abcm:FinalDividendForTheYearEndedJuneThirtyTwoThousandEighteenMember 2017-07-01 2018-06-30 0001492074 abcm:BioVisionAcquisitionMember 2021-10-26 0001492074 abcm:BioVisionAcquisitionMember abcm:CashFreeDebtFreeBasisMember 2021-10-26 0001492074 abcm:BioVisionAcquisitionMember 2021-10-26 2021-10-26 0001492074 abcm:BioVisionAcquisitionMember 2021-10-25 0001492074 abcm:BioVisionAcquisitionMember 2021-10-26 2021-12-31 0001492074 abcm:BioVisionAcquisitionMember 2021-12-31 2021-12-31 0001492074 abcm:ExpedeonAcquisitionMember 2020-01-01 0001492074 abcm:ExpedeonAcquisitionMember 2020-01-01 2020-01-01 0001492074 abcm:GeneEditingAndOncologyBusinessAcquisitionMember 2020-01-30 0001492074 abcm:GeneEditingAndOncologyBusinessAcquisitionMember 2020-01-30 2020-06-30 0001492074 abcm:MarkerGeneTechnologiesIncAcquisitionMember 2020-03-04 0001492074 abcm:MarkerGeneTechnologiesIncAcquisitionMember 2020-03-04 2020-03-04 0001492074 abcm:MarkerGeneTechnologiesIncAcquisitionMember 2020-03-04 2020-06-30 0001492074 abcm:CalicoAcquisitionMember 2019-01-24 0001492074 abcm:CalicoAcquisitionMember 2019-01-24 2019-06-30 0001492074 abcm:CalicoAcquisitionMember 2019-06-30 2019-06-30 0001492074 abcm:AbshareEmployeeShareSchemeMember 2018-01-01 2018-12-31 0001492074 abcm:ShareIncentivePlanAwardsMember 2018-10-01 2018-10-31 0001492074 abcm:FreeSharesMember abcm:PerTaxYearMember abcm:ShareIncentivePlanAwardsMember 2018-10-01 2018-10-31 0001492074 abcm:PerTaxYearMember abcm:ShareIncentivePlanAwardsMember 2018-10-31 0001492074 abcm:RevolvingCreditFacilityMember 2021-01-07 2021-01-07 0001492074 abcm:ExtensionOfMaturityDateMember abcm:RevolvingCreditFacilityMember 2020-12-17 2020-12-17 0001492074 abcm:RevolvingCreditFacilityMember 2019-02-01 0001492074 abcm:RevolvingCreditFacilityMember 2020-02-01 2020-02-29 0001492074 ifrs-full:IssuedCapitalMember 2021-12-31 0001492074 ifrs-full:SharePremiumMember 2021-12-31 0001492074 ifrs-full:MergerReserveMember 2021-12-31 0001492074 ifrs-full:TreasurySharesMember 2021-12-31 0001492074 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-12-31 0001492074 ifrs-full:ReserveOfCashFlowHedgesMember 2021-12-31 0001492074 ifrs-full:RetainedEarningsMember 2021-12-31 0001492074 abcm:CostAndCarryingAmountMember 2020-12-31 0001492074 abcm:CostAndCarryingAmountMember 2021-12-31 0001492074 abcm:CostAndCarryingAmountMember abcm:BioVisionCguMember 2021-12-31 0001492074 abcm:CostAndCarryingAmountMember abcm:GroupCguMember 2021-12-31 0001492074 abcm:DeferredTaxLiabilitiesNetMember ifrs-full:CashFlowHedgesMember 2021-12-31 0001492074 abcm:DeferredTaxLiabilitiesNetMember 2021-12-31 0001492074 ifrs-full:OtherTemporaryDifferencesMember abcm:DeferredTaxLiabilitiesNetMember 2021-12-31 0001492074 ifrs-full:UnusedTaxLossesMember abcm:DeferredTaxLiabilitiesNetMember 2021-12-31 0001492074 abcm:AcquiredIntangibleAssetsMember abcm:DeferredTaxLiabilitiesNetMember 2021-12-31 0001492074 abcm:ShareBasedPaymentsMember abcm:DeferredTaxLiabilitiesNetMember 2021-12-31 0001492074 abcm:AcceleratedCapitalAllowancesMember abcm:DeferredTaxLiabilitiesNetMember 2021-12-31 0001492074 abcm:AccumulatedDepreciationMember 2021-12-31 0001492074 ifrs-full:LeaseholdImprovementsMember abcm:AccumulatedDepreciationMember 2021-12-31 0001492074 abcm:CellLineAssetsMember abcm:AccumulatedDepreciationMember 2021-12-31 0001492074 abcm:OfficeFixturesFittingsAndOtherEquipmentMember abcm:AccumulatedDepreciationMember 2021-12-31 0001492074 abcm:LaboratoryEquipmentMember abcm:AccumulatedDepreciationMember 2021-12-31 0001492074 ifrs-full:LeaseholdImprovementsMember ifrs-full:GrossCarryingAmountMember 2021-12-31 0001492074 abcm:CellLineAssetsMember ifrs-full:GrossCarryingAmountMember 2021-12-31 0001492074 abcm:OfficeFixturesFittingsAndOtherEquipmentMember ifrs-full:GrossCarryingAmountMember 2021-12-31 0001492074 abcm:LaboratoryEquipmentMember ifrs-full:GrossCarryingAmountMember 2021-12-31 0001492074 abcm:ProfitableGrowthIncentivePlanAwardsMember 2020-12-31 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2021-12-31 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2021-12-31 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2021-12-31 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2021-12-31 0001492074 abcm:AcquisitionIntangiblesMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2021-12-31 0001492074 ifrs-full:ComputerSoftwareMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2021-12-31 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:InternallyGeneratedMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2021-12-31 0001492074 abcm:PatentsAndLicensesMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2021-12-31 0001492074 ifrs-full:IntangibleAssetsUnderDevelopmentMember 2021-12-31 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2021-12-31 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2021-12-31 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2021-12-31 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2021-12-31 0001492074 abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2021-12-31 0001492074 ifrs-full:ComputerSoftwareMember abcm:AccumulatedAmortizationMember 2021-12-31 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:InternallyGeneratedMember abcm:AccumulatedAmortizationMember 2021-12-31 0001492074 abcm:PatentsAndLicensesMember abcm:AccumulatedAmortizationMember 2021-12-31 0001492074 abcm:AccumulatedAmortizationMember 2021-12-31 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember 2021-12-31 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember 2021-12-31 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember 2021-12-31 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember 2021-12-31 0001492074 abcm:AcquisitionIntangiblesMember 2021-12-31 0001492074 ifrs-full:ComputerSoftwareMember 2021-12-31 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:InternallyGeneratedMember 2021-12-31 0001492074 abcm:PatentsAndLicensesMember 2021-12-31 0001492074 abcm:PatentsAndLicensesMember ifrs-full:GrossCarryingAmountMember 2021-12-31 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:GrossCarryingAmountMember ifrs-full:InternallyGeneratedMember 2021-12-31 0001492074 ifrs-full:ComputerSoftwareMember ifrs-full:GrossCarryingAmountMember 2021-12-31 0001492074 abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2021-12-31 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2021-12-31 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2021-12-31 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2021-12-31 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2021-12-31 0001492074 ifrs-full:OtherAssetsMember 2021-12-31 0001492074 ifrs-full:LandAndBuildingsMember 2021-12-31 0001492074 ifrs-full:OtherAssetsMember abcm:AccumulatedAmortizationMember 2021-12-31 0001492074 ifrs-full:LandAndBuildingsMember abcm:AccumulatedAmortizationMember 2021-12-31 0001492074 ifrs-full:LandAndBuildingsMember ifrs-full:GrossCarryingAmountMember 2021-12-31 0001492074 ifrs-full:OtherAssetsMember ifrs-full:GrossCarryingAmountMember 2021-12-31 0001492074 ifrs-full:IssuedCapitalMember 2020-12-31 0001492074 ifrs-full:SharePremiumMember 2020-12-31 0001492074 ifrs-full:MergerReserveMember 2020-12-31 0001492074 ifrs-full:TreasurySharesMember 2020-12-31 0001492074 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2020-12-31 0001492074 ifrs-full:ReserveOfCashFlowHedgesMember 2020-12-31 0001492074 ifrs-full:RetainedEarningsMember 2020-12-31 0001492074 abcm:CostAndCarryingAmountMember 2020-06-30 0001492074 abcm:CostAndCarryingAmountMember abcm:BioVisionCguMember 2020-12-31 0001492074 abcm:CostAndCarryingAmountMember abcm:GroupCguMember 2020-12-31 0001492074 abcm:DeferredTaxLiabilitiesNetMember 2020-12-31 0001492074 ifrs-full:OtherTemporaryDifferencesMember abcm:DeferredTaxLiabilitiesNetMember 2020-12-31 0001492074 ifrs-full:UnusedTaxLossesMember abcm:DeferredTaxLiabilitiesNetMember 2020-12-31 0001492074 abcm:AcquiredIntangibleAssetsMember abcm:DeferredTaxLiabilitiesNetMember 2020-12-31 0001492074 abcm:ShareBasedPaymentsMember abcm:DeferredTaxLiabilitiesNetMember 2020-12-31 0001492074 abcm:AcceleratedCapitalAllowancesMember abcm:DeferredTaxLiabilitiesNetMember 2020-12-31 0001492074 abcm:DeferredTaxLiabilitiesNetMember ifrs-full:CashFlowHedgesMember 2020-12-31 0001492074 abcm:AccumulatedDepreciationMember 2020-12-31 0001492074 ifrs-full:LeaseholdImprovementsMember abcm:AccumulatedDepreciationMember 2020-12-31 0001492074 abcm:CellLineAssetsMember abcm:AccumulatedDepreciationMember 2020-12-31 0001492074 abcm:OfficeFixturesFittingsAndOtherEquipmentMember abcm:AccumulatedDepreciationMember 2020-12-31 0001492074 abcm:LaboratoryEquipmentMember abcm:AccumulatedDepreciationMember 2020-12-31 0001492074 ifrs-full:LeaseholdImprovementsMember ifrs-full:GrossCarryingAmountMember 2020-12-31 0001492074 abcm:CellLineAssetsMember ifrs-full:GrossCarryingAmountMember 2020-12-31 0001492074 abcm:OfficeFixturesFittingsAndOtherEquipmentMember ifrs-full:GrossCarryingAmountMember 2020-12-31 0001492074 abcm:LaboratoryEquipmentMember ifrs-full:GrossCarryingAmountMember 2020-12-31 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2020-12-31 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2020-12-31 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2020-12-31 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2020-12-31 0001492074 abcm:AcquisitionIntangiblesMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2020-12-31 0001492074 ifrs-full:ComputerSoftwareMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2020-12-31 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:InternallyGeneratedMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2020-12-31 0001492074 abcm:PatentsAndLicensesMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2020-12-31 0001492074 ifrs-full:IntangibleAssetsUnderDevelopmentMember 2020-12-31 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2020-12-31 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2020-12-31 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2020-12-31 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2020-12-31 0001492074 abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2020-12-31 0001492074 ifrs-full:ComputerSoftwareMember abcm:AccumulatedAmortizationMember 2020-12-31 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:InternallyGeneratedMember abcm:AccumulatedAmortizationMember 2020-12-31 0001492074 abcm:PatentsAndLicensesMember abcm:AccumulatedAmortizationMember 2020-12-31 0001492074 abcm:AccumulatedAmortizationMember 2020-12-31 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2020-12-31 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2020-12-31 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember 2020-12-31 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember 2020-12-31 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember 2020-12-31 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember 2020-12-31 0001492074 abcm:AcquisitionIntangiblesMember 2020-12-31 0001492074 ifrs-full:ComputerSoftwareMember 2020-12-31 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:InternallyGeneratedMember 2020-12-31 0001492074 abcm:PatentsAndLicensesMember 2020-12-31 0001492074 abcm:PatentsAndLicensesMember ifrs-full:GrossCarryingAmountMember 2020-12-31 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:GrossCarryingAmountMember ifrs-full:InternallyGeneratedMember 2020-12-31 0001492074 ifrs-full:ComputerSoftwareMember ifrs-full:GrossCarryingAmountMember 2020-12-31 0001492074 abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2020-12-31 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2020-12-31 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2020-12-31 0001492074 ifrs-full:OtherAssetsMember 2020-12-31 0001492074 ifrs-full:OtherAssetsMember ifrs-full:GrossCarryingAmountMember 2020-12-31 0001492074 ifrs-full:LandAndBuildingsMember ifrs-full:GrossCarryingAmountMember 2020-12-31 0001492074 ifrs-full:LandAndBuildingsMember 2020-12-31 0001492074 ifrs-full:OtherAssetsMember abcm:AccumulatedAmortizationMember 2020-12-31 0001492074 ifrs-full:LandAndBuildingsMember abcm:AccumulatedAmortizationMember 2020-12-31 0001492074 ifrs-full:IssuedCapitalMember ifrs-full:PreviouslyStatedMember 2018-06-30 0001492074 ifrs-full:SharePremiumMember ifrs-full:PreviouslyStatedMember 2018-06-30 0001492074 ifrs-full:MergerReserveMember ifrs-full:PreviouslyStatedMember 2018-06-30 0001492074 ifrs-full:TreasurySharesMember ifrs-full:PreviouslyStatedMember 2018-06-30 0001492074 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember ifrs-full:PreviouslyStatedMember 2018-06-30 0001492074 ifrs-full:ReserveOfCashFlowHedgesMember ifrs-full:PreviouslyStatedMember 2018-06-30 0001492074 ifrs-full:RetainedEarningsMember ifrs-full:PreviouslyStatedMember 2018-06-30 0001492074 ifrs-full:PreviouslyStatedMember 2018-06-30 0001492074 ifrs-full:RetainedEarningsMember ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember 2018-06-30 0001492074 ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember 2018-06-30 0001492074 ifrs-full:RetainedEarningsMember 2018-06-30 0001492074 ifrs-full:IssuedCapitalMember 2018-06-30 0001492074 ifrs-full:SharePremiumMember 2018-06-30 0001492074 ifrs-full:MergerReserveMember 2018-06-30 0001492074 ifrs-full:TreasurySharesMember 2018-06-30 0001492074 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2018-06-30 0001492074 ifrs-full:ReserveOfCashFlowHedgesMember 2018-06-30 0001492074 ifrs-full:IssuedCapitalMember 2019-06-30 0001492074 ifrs-full:SharePremiumMember 2019-06-30 0001492074 ifrs-full:MergerReserveMember 2019-06-30 0001492074 ifrs-full:TreasurySharesMember 2019-06-30 0001492074 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2019-06-30 0001492074 ifrs-full:ReserveOfCashFlowHedgesMember 2019-06-30 0001492074 ifrs-full:RetainedEarningsMember 2019-06-30 0001492074 abcm:CostAndCarryingAmountMember 2018-06-30 0001492074 abcm:CostAndCarryingAmountMember 2019-06-30 0001492074 abcm:CostAndCarryingAmountMember abcm:BioVisionCguMember 2019-06-30 0001492074 abcm:GroupCguMember abcm:CostAndCarryingAmountMember 2019-06-30 0001492074 ifrs-full:PreviouslyStatedMember abcm:AcceleratedCapitalAllowancesMember abcm:DeferredTaxLiabilitiesNetMember 2018-06-30 0001492074 ifrs-full:PreviouslyStatedMember abcm:ShareBasedPaymentsMember abcm:DeferredTaxLiabilitiesNetMember 2018-06-30 0001492074 ifrs-full:PreviouslyStatedMember abcm:AcquiredIntangibleAssetsMember abcm:DeferredTaxLiabilitiesNetMember 2018-06-30 0001492074 ifrs-full:PreviouslyStatedMember ifrs-full:UnusedTaxLossesMember abcm:DeferredTaxLiabilitiesNetMember 2018-06-30 0001492074 ifrs-full:PreviouslyStatedMember ifrs-full:OtherTemporaryDifferencesMember abcm:DeferredTaxLiabilitiesNetMember 2018-06-30 0001492074 ifrs-full:PreviouslyStatedMember abcm:DeferredTaxLiabilitiesNetMember 2018-06-30 0001492074 ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember abcm:AcceleratedCapitalAllowancesMember abcm:DeferredTaxLiabilitiesNetMember 2018-06-30 0001492074 ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember abcm:DeferredTaxLiabilitiesNetMember 2018-06-30 0001492074 abcm:AcceleratedCapitalAllowancesMember abcm:DeferredTaxLiabilitiesNetMember 2018-06-30 0001492074 abcm:ShareBasedPaymentsMember abcm:DeferredTaxLiabilitiesNetMember 2018-06-30 0001492074 abcm:AcquiredIntangibleAssetsMember abcm:DeferredTaxLiabilitiesNetMember 2018-06-30 0001492074 ifrs-full:UnusedTaxLossesMember abcm:DeferredTaxLiabilitiesNetMember 2018-06-30 0001492074 ifrs-full:OtherTemporaryDifferencesMember abcm:DeferredTaxLiabilitiesNetMember 2018-06-30 0001492074 abcm:DeferredTaxLiabilitiesNetMember 2018-06-30 0001492074 abcm:DeferredTaxLiabilitiesNetMember ifrs-full:PreviouslyStatedMember ifrs-full:CashFlowHedgesMember 2018-06-30 0001492074 abcm:DeferredTaxLiabilitiesNetMember ifrs-full:CashFlowHedgesMember 2018-06-30 0001492074 abcm:DeferredTaxLiabilitiesNetMember 2019-06-30 0001492074 ifrs-full:OtherTemporaryDifferencesMember abcm:DeferredTaxLiabilitiesNetMember 2019-06-30 0001492074 ifrs-full:UnusedTaxLossesMember abcm:DeferredTaxLiabilitiesNetMember 2019-06-30 0001492074 abcm:AcquiredIntangibleAssetsMember abcm:DeferredTaxLiabilitiesNetMember 2019-06-30 0001492074 abcm:ShareBasedPaymentsMember abcm:DeferredTaxLiabilitiesNetMember 2019-06-30 0001492074 ifrs-full:CashFlowHedgesMember abcm:DeferredTaxLiabilitiesNetMember 2019-06-30 0001492074 abcm:AcceleratedCapitalAllowancesMember abcm:DeferredTaxLiabilitiesNetMember 2019-06-30 0001492074 ifrs-full:GrossCarryingAmountMember abcm:LaboratoryEquipmentMember 2018-06-30 0001492074 ifrs-full:GrossCarryingAmountMember abcm:OfficeFixturesFittingsAndOtherEquipmentMember 2018-06-30 0001492074 ifrs-full:GrossCarryingAmountMember abcm:CellLineAssetsMember 2018-06-30 0001492074 ifrs-full:GrossCarryingAmountMember ifrs-full:LeaseholdImprovementsMember 2018-06-30 0001492074 ifrs-full:GrossCarryingAmountMember 2018-06-30 0001492074 abcm:AccumulatedDepreciationMember abcm:LaboratoryEquipmentMember 2018-06-30 0001492074 abcm:AccumulatedDepreciationMember abcm:OfficeFixturesFittingsAndOtherEquipmentMember 2018-06-30 0001492074 abcm:AccumulatedDepreciationMember abcm:CellLineAssetsMember 2018-06-30 0001492074 abcm:AccumulatedDepreciationMember ifrs-full:LeaseholdImprovementsMember 2018-06-30 0001492074 abcm:AccumulatedDepreciationMember 2018-06-30 0001492074 abcm:AccumulatedDepreciationMember 2019-06-30 0001492074 ifrs-full:LeaseholdImprovementsMember abcm:AccumulatedDepreciationMember 2019-06-30 0001492074 abcm:CellLineAssetsMember abcm:AccumulatedDepreciationMember 2019-06-30 0001492074 abcm:OfficeFixturesFittingsAndOtherEquipmentMember abcm:AccumulatedDepreciationMember 2019-06-30 0001492074 abcm:LaboratoryEquipmentMember abcm:AccumulatedDepreciationMember 2019-06-30 0001492074 ifrs-full:LeaseholdImprovementsMember ifrs-full:GrossCarryingAmountMember 2019-06-30 0001492074 abcm:CellLineAssetsMember ifrs-full:GrossCarryingAmountMember 2019-06-30 0001492074 abcm:OfficeFixturesFittingsAndOtherEquipmentMember ifrs-full:GrossCarryingAmountMember 2019-06-30 0001492074 abcm:LaboratoryEquipmentMember ifrs-full:GrossCarryingAmountMember 2019-06-30 0001492074 abcm:LongTermIncentivePlanAwardsAndDeferredShareAwardMember 2018-06-30 0001492074 abcm:AbShareAwardsMember 2018-06-30 0001492074 abcm:ShareIncentivePlanAwardsMember abcm:MatchingSharesMember 2018-06-30 0001492074 abcm:ShareIncentivePlanAwardsMember abcm:FreeSharesMember 2018-06-30 0001492074 ifrs-full:PreviouslyStatedMember ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2018-06-30 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2018-06-30 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2018-06-30 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2018-06-30 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2018-06-30 0001492074 abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2018-06-30 0001492074 ifrs-full:ComputerSoftwareMember abcm:AccumulatedAmortizationMember 2018-06-30 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:InternallyGeneratedMember abcm:AccumulatedAmortizationMember 2018-06-30 0001492074 abcm:PatentsAndLicensesMember abcm:AccumulatedAmortizationMember 2018-06-30 0001492074 abcm:AccumulatedAmortizationMember 2018-06-30 0001492074 abcm:PatentsAndLicensesMember ifrs-full:GrossCarryingAmountMember 2018-06-30 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:GrossCarryingAmountMember ifrs-full:InternallyGeneratedMember 2018-06-30 0001492074 ifrs-full:ComputerSoftwareMember ifrs-full:GrossCarryingAmountMember 2018-06-30 0001492074 abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2018-06-30 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2018-06-30 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2018-06-30 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2018-06-30 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2018-06-30 0001492074 ifrs-full:GrossCarryingAmountMember ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember 2018-06-30 0001492074 abcm:PatentsAndLicensesMember ifrs-full:GrossCarryingAmountMember ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember 2018-06-30 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:GrossCarryingAmountMember ifrs-full:InternallyGeneratedMember ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember 2018-06-30 0001492074 ifrs-full:ComputerSoftwareMember ifrs-full:GrossCarryingAmountMember ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember 2018-06-30 0001492074 abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember 2018-06-30 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember 2018-06-30 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember 2018-06-30 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember 2018-06-30 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember 2018-06-30 0001492074 ifrs-full:PreviouslyStatedMember ifrs-full:GrossCarryingAmountMember 2018-06-30 0001492074 ifrs-full:PreviouslyStatedMember abcm:PatentsAndLicensesMember ifrs-full:GrossCarryingAmountMember 2018-06-30 0001492074 ifrs-full:PreviouslyStatedMember ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:GrossCarryingAmountMember ifrs-full:InternallyGeneratedMember 2018-06-30 0001492074 ifrs-full:PreviouslyStatedMember ifrs-full:ComputerSoftwareMember ifrs-full:GrossCarryingAmountMember 2018-06-30 0001492074 ifrs-full:PreviouslyStatedMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2018-06-30 0001492074 ifrs-full:PreviouslyStatedMember ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2018-06-30 0001492074 ifrs-full:PreviouslyStatedMember ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2018-06-30 0001492074 ifrs-full:PreviouslyStatedMember ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2018-06-30 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2019-06-30 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2019-06-30 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2019-06-30 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2019-06-30 0001492074 abcm:AcquisitionIntangiblesMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2019-06-30 0001492074 ifrs-full:ComputerSoftwareMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2019-06-30 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:InternallyGeneratedMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2019-06-30 0001492074 abcm:PatentsAndLicensesMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2019-06-30 0001492074 ifrs-full:IntangibleAssetsUnderDevelopmentMember 2019-06-30 0001492074 abcm:AccumulatedAmortizationMember 2019-06-30 0001492074 abcm:PatentsAndLicensesMember abcm:AccumulatedAmortizationMember 2019-06-30 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:InternallyGeneratedMember abcm:AccumulatedAmortizationMember 2019-06-30 0001492074 ifrs-full:ComputerSoftwareMember abcm:AccumulatedAmortizationMember 2019-06-30 0001492074 abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2019-06-30 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2019-06-30 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2019-06-30 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2019-06-30 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2019-06-30 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2019-06-30 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2019-06-30 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2019-06-30 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2019-06-30 0001492074 abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2019-06-30 0001492074 ifrs-full:ComputerSoftwareMember ifrs-full:GrossCarryingAmountMember 2019-06-30 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:GrossCarryingAmountMember ifrs-full:InternallyGeneratedMember 2019-06-30 0001492074 abcm:PatentsAndLicensesMember ifrs-full:GrossCarryingAmountMember 2019-06-30 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember 2019-06-30 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember 2019-06-30 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember 2019-06-30 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember 2019-06-30 0001492074 abcm:AcquisitionIntangiblesMember 2019-06-30 0001492074 ifrs-full:ComputerSoftwareMember 2019-06-30 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:InternallyGeneratedMember 2019-06-30 0001492074 abcm:PatentsAndLicensesMember 2019-06-30 0001492074 ifrs-full:RetainedEarningsMember abcm:Ifrs16Member 2020-06-30 0001492074 abcm:Ifrs16Member 2020-06-30 0001492074 abcm:RestatedBalanceMember ifrs-full:IssuedCapitalMember 2020-06-30 0001492074 abcm:RestatedBalanceMember ifrs-full:SharePremiumMember 2020-06-30 0001492074 abcm:RestatedBalanceMember ifrs-full:MergerReserveMember 2020-06-30 0001492074 abcm:RestatedBalanceMember ifrs-full:TreasurySharesMember 2020-06-30 0001492074 abcm:RestatedBalanceMember ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2020-06-30 0001492074 abcm:RestatedBalanceMember ifrs-full:ReserveOfCashFlowHedgesMember 2020-06-30 0001492074 abcm:RestatedBalanceMember ifrs-full:RetainedEarningsMember 2020-06-30 0001492074 ifrs-full:IssuedCapitalMember 2020-06-30 0001492074 ifrs-full:SharePremiumMember 2020-06-30 0001492074 ifrs-full:MergerReserveMember 2020-06-30 0001492074 ifrs-full:TreasurySharesMember 2020-06-30 0001492074 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2020-06-30 0001492074 ifrs-full:ReserveOfCashFlowHedgesMember 2020-06-30 0001492074 ifrs-full:RetainedEarningsMember 2020-06-30 0001492074 abcm:CostAndCarryingAmountMember abcm:BioVisionCguMember 2020-06-30 0001492074 abcm:CostAndCarryingAmountMember abcm:GroupCguMember 2020-06-30 0001492074 abcm:DeferredTaxLiabilitiesNetMember 2020-06-30 0001492074 ifrs-full:OtherTemporaryDifferencesMember abcm:DeferredTaxLiabilitiesNetMember 2020-06-30 0001492074 ifrs-full:UnusedTaxLossesMember abcm:DeferredTaxLiabilitiesNetMember 2020-06-30 0001492074 abcm:AcquiredIntangibleAssetsMember abcm:DeferredTaxLiabilitiesNetMember 2020-06-30 0001492074 abcm:ShareBasedPaymentsMember abcm:DeferredTaxLiabilitiesNetMember 2020-06-30 0001492074 ifrs-full:CashFlowHedgesMember abcm:DeferredTaxLiabilitiesNetMember 2020-06-30 0001492074 abcm:AcceleratedCapitalAllowancesMember abcm:DeferredTaxLiabilitiesNetMember 2020-06-30 0001492074 ifrs-full:GrossCarryingAmountMember ifrs-full:LandAndBuildingsMember 2019-06-30 0001492074 ifrs-full:GrossCarryingAmountMember ifrs-full:OtherAssetsMember 2019-06-30 0001492074 abcm:AccumulatedAmortizationMember ifrs-full:LandAndBuildingsMember 2019-06-30 0001492074 abcm:AccumulatedAmortizationMember ifrs-full:OtherAssetsMember 2019-06-30 0001492074 abcm:AccumulatedDepreciationMember 2020-06-30 0001492074 ifrs-full:LeaseholdImprovementsMember abcm:AccumulatedDepreciationMember 2020-06-30 0001492074 abcm:CellLineAssetsMember abcm:AccumulatedDepreciationMember 2020-06-30 0001492074 abcm:OfficeFixturesFittingsAndOtherEquipmentMember abcm:AccumulatedDepreciationMember 2020-06-30 0001492074 abcm:LaboratoryEquipmentMember abcm:AccumulatedDepreciationMember 2020-06-30 0001492074 ifrs-full:LeaseholdImprovementsMember ifrs-full:GrossCarryingAmountMember 2020-06-30 0001492074 abcm:CellLineAssetsMember ifrs-full:GrossCarryingAmountMember 2020-06-30 0001492074 abcm:OfficeFixturesFittingsAndOtherEquipmentMember ifrs-full:GrossCarryingAmountMember 2020-06-30 0001492074 abcm:LaboratoryEquipmentMember ifrs-full:GrossCarryingAmountMember 2020-06-30 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2020-06-30 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2020-06-30 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2020-06-30 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2020-06-30 0001492074 abcm:AcquisitionIntangiblesMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2020-06-30 0001492074 ifrs-full:ComputerSoftwareMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2020-06-30 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:InternallyGeneratedMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2020-06-30 0001492074 abcm:PatentsAndLicensesMember ifrs-full:IntangibleAssetsUnderDevelopmentMember 2020-06-30 0001492074 ifrs-full:IntangibleAssetsUnderDevelopmentMember 2020-06-30 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2020-06-30 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2020-06-30 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2020-06-30 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2020-06-30 0001492074 abcm:AcquisitionIntangiblesMember abcm:AccumulatedAmortizationMember 2020-06-30 0001492074 ifrs-full:ComputerSoftwareMember abcm:AccumulatedAmortizationMember 2020-06-30 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:InternallyGeneratedMember abcm:AccumulatedAmortizationMember 2020-06-30 0001492074 abcm:PatentsAndLicensesMember abcm:AccumulatedAmortizationMember 2020-06-30 0001492074 abcm:AccumulatedAmortizationMember 2020-06-30 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember 2020-06-30 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember 2020-06-30 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember 2020-06-30 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember 2020-06-30 0001492074 abcm:AcquisitionIntangiblesMember 2020-06-30 0001492074 ifrs-full:ComputerSoftwareMember 2020-06-30 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:InternallyGeneratedMember 2020-06-30 0001492074 abcm:PatentsAndLicensesMember 2020-06-30 0001492074 ifrs-full:ComputerSoftwareMember ifrs-full:GrossCarryingAmountMember 2020-06-30 0001492074 abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2020-06-30 0001492074 ifrs-full:BrandNamesMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2020-06-30 0001492074 ifrs-full:LicencesMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2020-06-30 0001492074 ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2020-06-30 0001492074 ifrs-full:CustomerrelatedIntangibleAssetsMember abcm:AcquisitionIntangiblesMember ifrs-full:GrossCarryingAmountMember 2020-06-30 0001492074 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:GrossCarryingAmountMember ifrs-full:InternallyGeneratedMember 2020-06-30 0001492074 abcm:PatentsAndLicensesMember ifrs-full:GrossCarryingAmountMember 2020-06-30 0001492074 ifrs-full:OtherAssetsMember ifrs-full:GrossCarryingAmountMember 2020-06-30 0001492074 ifrs-full:LandAndBuildingsMember ifrs-full:GrossCarryingAmountMember 2020-06-30 0001492074 ifrs-full:OtherAssetsMember 2020-06-30 0001492074 ifrs-full:LandAndBuildingsMember 2020-06-30 0001492074 ifrs-full:LandAndBuildingsMember abcm:AccumulatedAmortizationMember 2020-06-30 0001492074 ifrs-full:OtherAssetsMember abcm:AccumulatedAmortizationMember 2020-06-30 iso4217:GBP xbrli:pure xbrli:shares utr:Day iso4217:EUR iso4217:USD utr:Year utr:Month iso4217:GBP xbrli:shares iso4217:USD xbrli:shares utr:Y

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM

20-F/A

Amendment No. 1

(Mark One)

☐	REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

☒	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2021

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

☐	SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of event requiring this shell company report

Commission file number 001-39633

Abcam plc

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant’s name into English)

United Kingdom

(Jurisdiction of incorporation or organization)

Discovery Drive

Cambridge Biomedical Campus

Cambridge, CB2 0AX

United Kingdom

(Address of principal executive offices)

Alan Hirzel

Chief Executive Officer

Telephone: +44 (0) 1223 696000

Discovery Drive

Cambridge Biomedical Campus

Cambridge, CB2 0AX

United Kingdom

(Name, Telephone,

E-mail

and/or Facsimile number and Address of Company Contact Person)

Securities registered or to be registered, pursuant to Section 12(b) of the Act


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Ordinary shares, nominal value £0.002 per share*	ABCM	The Nasdaq Global Select Market

*	The ordinary shares are represented by American Depositary Shares, which are exempt from registration under Section 12(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder.

Securities registered or to be registered pursuant to Section 12(g) of the Act: None

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None

Indicate the number of outstanding shares of each of the issuer’s classes of capital stock or common stock as of the close of the period covered by the annual report:

228,883,639

ordinary shares, nominal value of £0.002 per share.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes ☐ No ☒

Note—Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation

S-T

(§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a

non-accelerated

filer, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule

12b-2

of the Exchange Act.


☒ Large accelerated filer		☐ Accelerated filer		☐ Non-accelerated filer		☐ Emerging growth company

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act. ☐

† The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:


☐ U.S. GAAP		☒ International Financial Reporting Standards as issued by the International Accounting Standards Board		☐ Other

If “Other” has been checked in response to the previous question indicate by check mark which financial statement item the registrant has elected to follow. Item 17 ☐ Item 18 ☐

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule

12b-2

of the Exchange Act). Yes ☐ No ☒


Auditor Firm Id: 876		Auditor Name: PricewaterhouseCoopers LLP		Auditor Location: Cambridge, United Kingdom

Explanatory Note

This Amendment No. 1 to the Annual Report on Form

20-F

of Abcam plc (the “Company”) amends the Company’s Annual Report on Form

20-F

for the year ended December 31, 2021 (the “Original

20-F”),

which was filed with the Securities and Exchange Commission on March 14, 2022. The Company is filing this Amendment No. 1 solely to file Exhibit 101, which was not included in the Original

20-F,

in accordance with Rule 405 of Regulation

S-T.

Exhibit 101 contains interactive data files in Inline eXtensible Business Reporting Language (XBRL).

Except as described above, this Amendment No. 1 does not, and does not purport to, amend, modify, update or restate any information set forth in the Original

20-F,

and the Company has not updated disclosures included therein to reflect any events that occurred subsequent to March 14, 2022.

PART III

Item 19. Exhibits


Exhibit No.		Description

101.INS*		Inline XBRL Instance Document — The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

101.SCH*		Inline XBRL Taxonomy Extension Schema Document

101.PRE*		Inline XBRL Taxonomy Presentation Linkbase Document

101.CAL*		Inline XBRL Taxonomy Calculation Linkbase Document

101.LAB*		Inline XBRL Taxonomy Label Linkbase Document

101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document

104*		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*	Filed herewith.

SIGNATURES

The registrant hereby certifies that it meets all of the requirements for filing on Form

20-F

and that it has duly caused and authorized the undersigned to sign this Amendment No. 1 to Annual Report on Form

20-F

on its behalf.


ABCAM PLC

Date: April 8, 2022

By:		/s/ Alan Hirzel
Name:		Alan Hirzel
Title:		Chief Executive Officer

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS


Report of Independent Registered Public Accounting Firm (PCAOB ID 876)			F-2
Consolidated income statements			F-5
Consolidated statements of comprehensive income			F-6
Consolidated balance sheets			F-7
Consolidated statements of changes in equity			F-8
Consolidated cash flow statements			F-9
Notes to the consolidated financial statements			F-10

F-1

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Shareholders of Abcam plc

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheet of Abcam plc and its subsidiaries (the “Group”) as of December 31, 2021, December 31, 2020 and June 30, 2020, and the related consolidated income statement, consolidated statement of comprehensive income, consolidated statement of changes in equity and consolidated cash flow statement for the year ended December 31, 2021, six-months ended December 31, 2020 and years ended June 30, 2020 and June 30, 2019, including the related notes (collectively referred to as the “consolidated financial statements”). We also have audited the Group’s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Group as of December 31, 2021, December 31, 2020 and June 30, 2020, and the results of its operations and its cash flows for the year ended December 31, 2021, six months ended December 31, 2020 and years ended June 30, 2020 and June 30, 2019 in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board. Also in our opinion, the Group did not maintain, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO because material weaknesses in internal control over financial reporting existed as of that date. The material weaknesses related to (i) lack of controls over information technology systems that are relevant to the preparation of the consolidated financial statements, (ii) insufficient controls over the completeness and accuracy of records for the goods received not invoiced account, (iii) ineffective controls in pricing, quantities and discount rates in the revenue cycle including review and approval of manual invoices, (iv) ineffective controls over the completeness, accuracy, existence and valuation of inventory, (v) insufficient controls over the preparation and review of payroll, including completeness and accuracy of key data inputs and (vi) insufficient controls over the completeness and accuracy of key data inputs in manual journal entries.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses referred to above are described in Management’s Annual Report on Internal Control over Financial Reporting appearing under Item 15. We considered these material weaknesses in determining the nature, timing, and extent of audit tests applied in our audit of the December 31, 2021 consolidated financial statements, and our opinion regarding the effectiveness of the Group’s internal control over financial reporting does not affect our opinion on those consolidated financial statements.

Changes in Accounting Principles

As discussed in notes 1 and 3 to the consolidated financial statements, the Group changed the manner in which it accounts for cloud computing costs in 2021 and the manner in which it accounts for leases as of July 1, 2019.

Basis for Opinions

The Group’s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in management’s report referred to above. Our responsibility is to express opinions on the Group’s consolidated financial statements and on the Group’s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Group in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

F-2

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

As described in Management’s Annual Report on Internal Control over Financial Reporting, management has excluded BioVision, Inc from its assessment of internal control over financial reporting as of December 31, 2021 because it was acquired by the Group in a purchase business combination during 2021. We have also excluded BioVision, Inc from our audit of internal control over financial reporting. BioVision, Inc is a wholly-owned subsidiary whose total assets and total revenues excluded from management’s assessment and our audit of internal control over financial reporting represent 2% and 1%, respectively, of the related consolidated financial statement amounts as of and for the year ended December 31, 2021.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Valuation of BioVision, Inc. acquired intangible assets

As described in notes 4 and 29 to the consolidated financial statements, on October 26, 2021 the Group acquired NKY Biotech US, Inc and its 100% owned subsidiary, BioVision, Inc (collectively “BioVision”), for cash consideration of $349.9 million (£253.8 million), which resulted in the recognition of intangible assets of £80.6 million. Management made significant judgement in estimating the fair value of the intangible assets acquired, which involved the use of significant estimates and assumptions with respect to the future cash flows. The significant assumptions used by management included the revenue growth rate and the expected attrition rates associated with the acquired product portfolio.

The principal considerations for our determination that performing procedures relating to the valuation of BioVision acquired intangible assets is a critical audit matter are (i) the significant judgment made by management in determining the fair value of the intangible assets acquired; (ii) a high degree of auditor

F-3

judgment, subjectivity, and effort in performing procedures and evaluating the significant assumptions related to the future cash flows, revenue growth rate and expected attrition rates associated with the acquired product portfolio; and (iii) the audit effort involved the use of professionals with specialized skills and knowledge.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included, among others (i) reading the purchase agreement and assessing the completeness of intangible assets identified and (ii) testing management’s process for determining the fair value of the acquired intangible assets. Testing management’s process included (a) evaluating the appropriateness of the valuation methods, (b) testing the mathematical accuracy of the model, (c) testing the completeness and accuracy of data used in the model and (d) evaluating the reasonableness of significant assumptions used by management in estimating the future cash flows. Evaluating management’s assumptions related to the revenue growth rate and expected attrition rates with the acquired product portfolio involved evaluating whether the assumptions used were reasonable considering consistency with external market and industry data and historical revenue growth rates. Professionals with specialized skill and knowledge were used to assist in evaluating the appropriateness of the management’s valuation methods and evaluating the reasonableness of the expected attrition rates assumption.

Impairment assessment of acquired intangible assets

As described in notes 4 and 13 to the consolidated financial statements, the Group holds intangible assets with a carrying value of £234.2 million as of December 31, 2021 which included technology acquired in the Firefly BioWorks acquisition of £11.3 million. Management regularly reviews for indicators of impairment of acquired intangible assets against qualitative and quantitative factors. During the period ended December 31, 2021, management performed an impairment assessment of the Firefly intangible asset. Management utilized the fair value less costs to sell method to assess the recoverable amount of the intangible assets. Management estimated the fair value of the intangible asset utilizing market-based data from comparable companies and recent transactions in the industry. The result was a fair value that significantly exceeded the carrying value of the asset and management has concluded that there are no reasonable possible scenarios that would cause an impairment to be required.

The principal considerations for our determination that performing procedures relating to the impairment assessment of acquired intangible assets is a critical audit matter are (i) the significant judgement made by management in determining the recoverable amount of the Firefly intangible asset; and (ii) a high degree of auditor judgement, subjectivity, and effort in performing procedures and evaluating management’s significant assumptions related to the appropriate comparable companies and recent transactions.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included, among others, (i) testing management’s process for estimating the recoverable amount of the Firefly intangible asset; (ii) evaluating the appropriateness of the methodology used to determine the fair value; (iii) testing the completeness and accuracy of the underlying data used in the models, and (iv) evaluating the reasonableness of significant assumptions when estimating the fair value. Evaluating management’s assumptions involved (a) determining the appropriateness of the comparable companies and recent transactions used by management and (b) considering other sources that corroborated or contradicted management’s assumptions.

/s/ PricewaterhouseCoopers LLP

Cambridge, United Kingdom

March 14, 2022

We have served as the Group’s auditor since 2013 which includes periods before the Group became subject to SEC reporting requirements.

F-4

Consolidated income statements

For the year ended 31 December 2021, the six months ended 31 December 2020 and the years ended 30 June 2020 and 2019


	Note		Year ended 31 December 2021 £m			Six months ended 31 December 2020 (revised*) £m			Year ended 30 June 2020 (revised*) £m			Year ended 30 June 2019 (revised*) £m
Revenue		5		315.4			147.5			260.0			259.9
Cost of sales				(90.8	)		(42.9	)		(79.8	)		(76.7	)

Gross profit				224.6			104.6			180.2			183.2
Selling, general and administrative expenses				(189.7	)		(73.6	)		(131.5	)		(112.9	)
Research and development expenses				(27.8	)		(13.7	)		(38.3	)		(15.0	)

Operating profit		6		7.1			17.3			10.4			55.3
Finance income		9		0.3			0.2			0.7			0.6
Finance costs		9		(2.7	)		(1.9	)		(2.8	)		(0.3	)

Profit before tax				4.7			15.6			8.3			55.6
Tax (charge) / credit		10		(0.3	)		(2.8	)		4.2			(11.2	)

Profit for the year / period attributable to equity shareholders of the parent				4.4			12.8			12.5			44.4

Earnings per share
Basic		11		1.9p			5.8p			6.0p			21.7p
Diluted		11		1.9p			5.8p			6.0p			21.5p

*	See note 1(d) for details related to the retrospective impact of a change in the Group’s accounting policy for cloud computing costs.

The accompanying accounting policies and notes form an integral part of these consolidated financial statements.

F-5

Consolidated statements of comprehensive income

For the year ended 31 December 2021, the six months ended 31 December 2020 and the years ended 30 June 2020 and 2019


	Note		Year ended 31 December 2021 £m			Six months ended 31 December 2020 (revised*) £m			Year ended 30 June 2020 (revised*) £m			Year ended 30 June 2019 (revised*) £m
Profit for the year / period attributable to equity shareholders of the parent				4.4			12.8			12.5			44.4

Items that may be reclassified to the income statement in subsequent years
Movement on cash flow hedges		26		(0.1	)		1.1			0.7			(1.7	)
Exchange differences on translation of foreign operations				5.7			(17.5	)		9.6			7.0
Movement in fair value of investment				(0.1	)		(3.1	)		4.0			(0.1	)
Tax relating to components of other comprehensive income				0.5			0.6			(1.5	)		0.3

Other comprehensive income / (expense) for the year / period				6.0			(18.9	)		12.8			5.5

Total comprehensive income / (expense) for the year / period				10.4			(6.1	)		25.3			49.9

*	See note 1(d) for details related to the retrospective impact of a change in the Group’s accounting policy for cloud computing costs.

The accompanying accounting policies and notes form an integral part of these consolidated financial statements.

F-6

Consolidated balance sheets

As at 31 December 2021, 31 December 2020 and 30 June 2020


	Note		As at 31 December 2021 £m			As at 31 December 2020 (revised*) £m			As at 30 June 2020 (revised*) £m
Non-current assets
Goodwill		12		364.8			184.3			195.0
Intangible assets		13		234.2			151.8			150.1
Property, plant and equipment		14		73.5			48.5			43.3
Right-of-use assets		15		88.2			108.8			121.4
Investments		16		3.5			3.4			7.0
Deferred tax asset		17		10.4			15.6			13.7

				774.6			512.4			530.5

Current assets
Inventories		18		58.2			42.9			40.7
Trade and other receivables		19		47.2			47.3			44.4
Current tax receivable				10.5			3.8			6.4
Derivative financial instruments		20		0.5			0.3			—
Cash and cash equivalents				95.1			211.9			187.3

				211.5			306.2			278.8

Total assets				986.1			818.6			809.3

Current liabilities
Trade and other payables		21		(54.2	)		(43.4	)		(43.8	)
Derivative financial instruments		20		(0.2	)		(0.1	)		(1.2	)
Lease liabilities		15		(9.2	)		(7.1	)		(7.3	)
Borrowings		22		(119.2	)		—			(106.4	)
Current tax liabilities				(4.4	)		(1.4	)		(0.9	)

				(187.2	)		(52.0	)		(159.6	)

Net current assets				24.3			254.2			119.2

Non-current liabilities
Deferred tax liability		17		(41.5	)		(27.6	)		(28.3	)
Lease liabilities		15		(101.3	)		(109.9	)		(120.5	)

				(142.8	)		(137.5	)		(148.8	)

Total liabilities				(330.0	)		(189.5	)		(308.4	)

Net assets				656.1			629.1			500.9

Equity
Share capital		23		0.5			0.5			0.4
Share premium account				268.3			265.1			138.2
Merger reserve		23		68.6			68.6			68.6
Own shares		23		(2.2	)		(2.4	)		(2.5	)
Translation reserve		23		31.1			25.4			42.9
Hedging reserve		23		0.2			0.2			(0.7	)
Retained earnings				289.6			271.7			254.0

Total equity attributable to the equity shareholders of the parent				656.1			629.1			500.9

*	See note 1(d) for details related to the retrospective impact of a change in the Group’s accounting policy for cloud computing costs.

The accompanying accounting policies and notes form an integral part of these consolidated financial statements.

F-7

Consolidated statements of changes in equity

For the year ended 31 December 2021, the six months ended 31 December 2020 and the years ended 30 June 2020 and 2019


	Note		Share capital £m		Share premium account £m		Merger reserve £m		Own shares £m			Translation Reserve £m			Hedging reserve £m			Retained Earnings £m			Total £m
Balance as at 1 July 2018				0.4		25.6		68.1		(3.2	)		26.3			0.1			234.4			351.7
Revision				—		—		—		—			—			—			(1.1	)		(1.1	)
Balance as at 1 July 2018 (revised*)				0.4		25.6		68.1		(3.2	)		26.3			0.1			233.3			350.6
Profit for the year (revised*)				—		—		—		—			—			—			44.4			44.4
Other comprehensive income / (expense) (revised*)				—		—		—		—			7.0			(1.4	)		(0.1	)		5.5
Total comprehensive income / (expense) for the year (revised*)				—		—		—		—			7.0			(1.4	)		44.3			49.9
Issue of ordinary shares, net of share issue costs				—		1.4		—		0.4			—			—			(0.4	)		1.4
Share-based payments inclusive of deferred tax				—		—		—		—			—			—			6.3			6.3
Purchase of own shares				—		—		—		—			—			—			(0.2	)		(0.2	)
Equity dividends		24		—		—		—		—			—			—			(24.9	)		(24.9	)
Balance as at 30 June 2019 (revised*)				0.4		27.0		68.1		(2.8	)		33.3			(1.3	)		258.4			383.1
Implementation of IFRS16				—		—		—		—			—			—			(1.5	)		(1.5	)
Balance as at 1 July 2019				0.4		27.0		68.1		(2.8	)		33.3			(1.3	)		256.9			381.6
Profit for the year (revised*)				—		—		—		—			—			—			12.5			12.5
Other comprehensive income (revised*)				—		—		—		—			9.6			0.6			2.6			12.8
Total comprehensive income for the year (revised*)				—		—		—		—			9.6			0.6			15.1			25.3
Issue of ordinary shares, net of share issue costs				—		111.2		0.5		0.3			—			—			(0.3	)		111.7
Share-based payments inclusive of deferred tax				—		—		—		—			—			—			7.4			7.4
Purchase of own shares				—		—		—		—			—			—			(0.1	)		(0.1	)
Equity dividends		24		—		—		—		—			—			—			(25.0	)		(25.0	)
Balance as at 30 June 2020 (revised*)				0.4		138.2		68.6		(2.5	)		42.9			(0.7	)		254.0			500.9
Profit for the period (revised*)				—		—		—		—			—			—			12.8			12.8
Other comprehensive (expense) / income (revised*)				—		—		—		—			(17.5	)		0.9			(2.3	)		(18.9	)
Total comprehensive (expense) / income for the period (revised*)				—		—		—		—			(17.5	)		0.9			10.5			(6.1	)
Issue of ordinary shares, net of share issue costs				0.1		126.9		—		0.1			—			—			(0.1	)		127.0
Share-based payments inclusive of deferred tax				—		—		—		—			—			—			7.4			7.4
Purchase of own shares				—		—		—		—			—			—			(0.1	)		(0.1	)
Balance as at 31 December 2020 (revised*)				0.5		265.1		68.6		(2.4	)		25.4			0.2			271.7			629.1
Profit for the year				—		—		—		—			—			—			4.4			4.4
Other comprehensive income				—		—		—		—			5.7			—			0.3			6.0
Total comprehensive income for the year				—		—		—		—			5.7			—			4.7			10.4
Issue of ordinary shares, net of share issue costs				—		3.2		—		0.2			—			—			(0.2	)		3.2
Share-based payments inclusive of deferred tax				—		—		—		—			—			—			13.4			13.4
Balance as at 31 December 2021				0.5		268.3		68.6		(2.2	)		31.1			0.2			289.6			656.1

*	See note 1 ( d) for details related to the retrospective impact of a change in the Group’s accounting policy for cloud computing costs.

The accompanying accounting policies and notes form an integral part of these consolidated financial statements.

F-8

Consolidated cash flow statements

For the year ended 31 December 2021, the six months ended 31 December 2020 and the years ended 30 June 2020 and 2019


	Note		Year ended 31 December 2021 £m			Six months ended 31 December 2020 (revised*) £m			Year ended 30 June 2020 (revised*) £m			Year ended 30 June 2019 (revised*) £m
Cash generated from operations		25		72.2			33.1			65.4			82.8
Net income taxes (paid) / received				(9.3	)		0.2			(2.4	)		(13.5	)

Net cash inflow from operating activities				62.9			33.3			63.0			69.3

Investing activities
Investment income				0.3			0.2			0.7			0.6
Purchase of property, plant and equipment				(34.5	)		(11.5	)		(12.7	)		(17.7	)
Purchase of intangible assets				(25.3	)		(13.0	)		(23.0	)		(21.8	)
Transfer of cash from / (to) escrow in respect of future capital expenditure				—			0.4			(0.6	)		4.5
Purchase of investments		16		(0.1	)		—			(2.2	)		—
Reimbursement of leasehold improvement costs				13.2			1.7			—			—
Net cash outflow arising from acquisitions		29		(245.1	)		—			(110.3	)		(14.6	)

Net cash outflow from investing activities				(291.5	)		(22.2	)		(148.1	)		(49.0	)

Financing activities
Dividends paid		24		—			—			(25.0	)		(24.9	)
Principal element of lease obligations				(8.8	)		(3.8	)		(6.8	)		—
Interest element of lease obligations				(1.5	)		(0.5	)		(0.9	)		—
Interest paid				(0.7	)		(0.6	)		(0.8	)		(0.1	)
Proceeds on issue of shares, net of issue costs				3.2			127.0			111.2			1.4
Facility arrangement fees				(0.8	)		—			—			(0.9	)
Utilisation of revolving credit facility		22		120.0			—			127.0			—
Repayment of revolving credit facility		22		—			(107.0	)		(20.0	)		—
Purchase of own shares				—			(0.1	)		(0.1	)		(0.2	)

Net cash inflow / (outflow) from financing activities				111.4			15.0			184.6			(24.7	)

Net (decrease) / increase cash and cash equivalents				(117.2	)		26.1			99.5			(4.4	)

Cash and cash equivalents at beginning of the year / period				211.9			187.3			87.1			90.2
Effect of foreign exchange rates on cash and cash equivalents				0.4			(1.5	)		0.7			1.3

Cash and cash equivalents at end of the year / period		(i)		95.1			211.9			187.3			87.1

*	See note 1 (d) for details related to the retrospective impact of a change in the Group’s accounting policy for cloud computing costs.

i)	Within cash and cash equivalents at 31 December 2021 is £nil (31 December 2020: £1.3m; 30 June 2020: £0.9m; 30 June 2019: £0.4m) of cash relating to employee contributions to the Group’s share scheme ‘AbShare’, which is reserved for the purpose of purchasing shares upon vesting.

F-9

Notes to the consolidated financial statements

For the year ended 31 December 2021, the six months ended 31 December 2020 and the years ended 30 June 2020 and 2019

1.	Presentation of financial statements

a)	General information

Abcam plc (the Company) is a public limited company, incorporated and domiciled in the UK and is registered in England under the Companies Act 2006. Abcam’s ordinary shares are listed on the Alternative Investment Market (AIM) of the London Stock Exchange and its American Depositary Shares trade on the Nasdaq Global Market.

b)	Basis of preparation and consolidation

On 2 June 2021, the Group announced that it was amending its financial year end date from 30 June to 31 December. These financial statements are therefore presented for the year ended 31 December 2021, the six months ended 31 December 2020 and the years ended 30 June 2020 and 2019.

The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board.

The consolidated financial statements have been presented in Sterling, the functional currency of the Company, and on the historical cost basis, except for the revaluation of certain financial instruments.

The consolidated financial statements incorporate the financial statements of the Company and entities under its control (together the ‘Group’).

Control is achieved when the Company has power to control the financial and operating policies of an entity either directly or indirectly and the ability to use that power to affect the returns it receives from its involvement with the entity.

Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies in line with those used by the Group. All intra-group transactions, balances, equity, income and expenses are eliminated on consolidation.

The Group’s subsidiary undertakings are shown in note 16 to these financial statements.

c)	Going concern

The Group meets its

day-to-day

working capital requirements from the cash surpluses generated as a result of normal trading. In considering going concern, the Directors have reviewed the Group’s forecasts and projections, taking account of reasonably possible changes in trading performance. These show that the Group should be able to operate within the limits of its available resources.

Accordingly, the Directors have a reasonable expectation that the Group has adequate resources to continue in operation for the foreseeable future and at least one year from the date of approval of the financial statements. For this reason, they continue to adopt the going concern basis in preparing its consolidated financial statements.

d)	Change in accounting policy—Software as a Service (‘SaaS’) arrangements

In March 2021, the IFRS Interpretations Committee (‘IFRIC’) published an agenda decision on how an entity should account for costs of configuring or customizing application software in a Cloud Computing or Software as a Service (‘SaaS’) arrangement.

Previously, internal and external costs incurred in connection with the various phases of the Group’s ERP implementation and other projects, have been capitalized as an intangible asset in line with IAS 38 ‘Intangible Assets’.

Following an internal review of the impact of adoption of the IFRIC, for those arrangements where the Group does not have control of the developed software, to the extent that the services were performed by third parties, the Group has derecognized the intangible asset previously capitalized.

F-

This change in accounting policy has led to adjustments amounting to a £

2.7

m, £

2.1

m, and £

2.1

m reduction in the intangible assets recognized in the

December 2020, 30

June 2020

and

June 2019

balance sheets, and to a net £

0.6

m, £

0.1

m and £

0.8

m increase in selling, general and administrative expenses in those respective periods.

The following tables summarize the impact of the adjustment to results for each comparative period presented:

Six months ended 31 December 2020:


	As previously reported £m			Adjustment £m			Revised £m
Impact on income statement

Selling, general and administrative expenses		(73.0	)		(0.6	)		(73.6	)
Operating profit		17.9			(0.6	)		17.3
Profit before tax		16.2			(0.6	)		15.6
Tax		(2.9	)		0.1			(2.8	)
Profit for the period		13.3			(0.5	)		12.8

Impact on statement of comprehensive income
Total comprehensive expense		(5.6	)		(0.5	)		(6.1	)

Earnings per share
Basic		6.1	p		(0.3	)p		5.8	p
Diluted		6.0	p		(0.2	)p		5.8	p

Impact on balance sheet
Intangible assets		154.5			(2.7	)		151.8
Total non-current assets		515.1			(2.7	)		512.4
Deferred tax liability		(28.1	)		0.5			(27.6	)
Total non-current liabilities		(138.0	)		0.5			(137.5	)
Net assets		631.3			(2.2	)		629.1
Retained earnings		273.9			(2.2	)		271.7
Total equity		631.3			(2.2	)		629.1

Impact on cash flow statement
Cash generated from operations		33.7			(0.6	)		33.1
Net cash inflow from operating activities		33.9			(0.6	)		33.3
Purchase of intangible assets		(13.6	)		0.6			(13.0	)
Net cash outflow from investing activities		(22.8	)		0.6			(22.2	)

F-

Year ended 30 June 2020:


	As previously reported £m			Adjustment £m			Revised £m
Impact on income statement

Selling, general and administrative expenses		(131.4	)		(0.1	)		(131.5	)
Operating profit		10.5			(0.1	)		10.4
Profit before tax		8.4			(0.1	)		8.3
Tax		4.1			0.1			4.2
Profit for the period		12.5			—			12.5

Impact on statement of comprehensive income
Total comprehensive income		25.3			—			25.3

Earnings per share
Basic		6.0	p		—			6.0	p
Diluted		6.0	p		—			6.0	p

Impact on balance sheet
Intangible assets		154.4			(2.1	)		152.3
Total non-current assets		532.6			(2.1	)		530.5
Deferred tax liability		(28.7	)		0.4			(28.3	)
Total non-current liabilities		(149.2	)		0.4			(148.8	)
Net assets		502.6			(1.7	)		500.9
Retained earnings		255.7			(1.7	)		254.0
Total equity		502.6			(1.7	)		500.9

Impact on cash flow statement
Cash generated from operations		65.4			—			65.4
Net cash inflow from operating activities		63.0			—			63.0
Purchase of intangible assets		(23.0	)		—			(23.0	)
Net cash outflow from investing activities		(148.1	)		—			(148.1	)

F-

Year ended 30 June 2019:


	As previously reported £m			Adjustment £m			Revised £m
Impact on income statement
Selling, general and administrative expenses		(112.1	)		(0.8	)		(112.9	)
Operating profit		56.1			(0.8	)		55.3
Profit before tax		56.4			(0.8	)		55.6
Tax		(11.4	)		0.2			(11.2	)
Profit for the period		45.0			(0.6	)		44.4

Earnings per share
Basic		22.0	p		(0.3	)p		21.7	p
Diluted		21.8	p		(0.3	)p		21.5	p

Impact on statement of comprehensive income
Total comprehensive income		50.5			(0.6	)		49.9

Impact on balance sheet
Intangible assets		106.7			(2.1	)		104.6
Total non-current assets		274.9			(2.1	)		272.8
Deferred tax liability		(16.5	)		0.4			(16.1	)
Total non-current liabilities		(16.6	)		0.4			(16.2	)
Net assets		384.8			(1.7	)		383.1
Retained earnings		260.1			(1.7	)		258.4
Total equity		384.8			(1.7	)		383.1

Impact on cash flow statement
Cash generated from operations		83.7			(0.9	)		82.2
Net cash inflow from operating activities		70.2			(0.9	)		69.3
Purchase of intangible assets		(22.7	)		0.9			(21.8	)
Net cash outflow from investing activities		(49.9	)		0.9			(49.0	)

Decrease in cash and cash equivalents		(4.4	)		—			(4.4	)

2.	New accounting standards, amendments and interpretations

Standards, amendments and interpretations effective or adopted

The following standards and amendments are effective in the group’s consolidated financial statements:

•

Amendments to IFRS 9, IAS 39 and IFRS 7 ‘Interest rate benchmark reform’;

•

Amendments to IAS 1 and IAS 8 ‘Definition of material’;

•

Amendments to IFRS 3 ‘Definition of a business’;

•

Amendments to references to the Conceptual Framework in IFRS standards; and

•

Amendments to IFRS 16

‘Covid-19-related

rent concessions’.

Amendments effective during the reporting period did not have any significant impact on adoption.

Standards, amendments and interpretations not yet effective and not early adopted

The following standards and amendments have not been adopted in the group’s consolidated financial statements as they are not yet effective:

•

Amendments to IFRS 16

‘Covid-19-related

rent concessions beyond 30 June 2021’ (effective from 1 April 2021);

•

Interest Rate Benchmark Reform—Phase 2 - Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 (mandatory for accounting periods beginning after 1 January 2021);

•

Amendments to IFRS 3 ‘References to the Conceptual Framework’ (effective from 1 January 2022, endorsed for use in the EU but not in the UK);

F-1

•

Amendments to IAS 16 ‘Property, plant and equipment—proceeds before intended use’ (effective from 1 January 2022, endorsed for use in the EU but not in the UK);

•

Amendments to IAS 37 ‘Onerous contracts—cost of fulfilling a contract’ (effective 1 January 2022, endorsed for use in the EU but not in the UK);

•

Annual Improvements 2018-2020 Cycle—amendments to IFRS 1, IFRS 9, IFRS 16 and IAS 41 (effective from 1 January 2022, endorsed for use in the EU but not in the UK);

•

Amendments to IFRS 17 ‘Insurance contracts’ (effective from 1 January 2023, not yet endorsed in the EU or UK);

•

Amendments to IAS 1 ‘Classification of liabilities as current or

non-current’

(effective from 1 January 2023, not yet endorsed in the EU or UK);

•

Amendments to IAS 1 and IFRS Practice Statement 2 ‘Disclosure of accounting policies’ (effective from 1 January 2023, not yet endorsed in the EU or UK);

•

Amendments to IAS 8 ‘Definition of accounting estimates’ (effective from 1 January 2023, not yet endorsed in the EU or UK);

and

•

Amendments to IAS 12 ‘Deferred tax related to assets and liabilities arising from a single transaction’ (effective from 1 January 2023, not yet endorsed in the EU or UK).

The amendments listed above are not expected to have a material impact on the financial statements of the Group in future periods.

3.	Principal accounting policies

Revenue and income recognition

Revenue is measured at the fair value of the consideration received or receivable and represents amounts receivable for goods and services, net of discounts, VAT and other sales-related taxes.

Revenue from sales of goods, including revenue generated from products sold from the Group’s catalogue and IVD and which represents the significant majority of the Group’s revenue, is recognized upon delivery to the customer or the point at which the customer takes control of the goods if this is sooner.

Custom product and service revenue, which can be the provision of a service or the development of products for customers, is recognized at the point at which a milestone, as defined in the contract, has been completed. Each milestone is typically aligned to a customer deliverable, for example, the amount of services provided, a deliverable arising from the services or the number of products successfully developed and provided to customers, and accordingly is considered to be a performance obligation. Every milestone has a defined transaction price. If it is identified that the costs will be in excess of the contract revenue, the expected loss is recognized as an expense immediately.

Licence fee income is recognized upon delivery of the licensed technology where the Group’s continued performance or future research and development services are not required. Royalty revenue is recognized on an accruals basis based on the contractual terms and the substance of the agreements with the counterparty, provided that the amount can be reliably measured and it is probable that the economic benefit will flow to the Group.

Leasing

Accounting policy applied from 1 July 2019 (IFRS 16)

Leased assets are capitalized on inception of the lease as

right-of-use

assets. A corresponding lease liability, representing the present value of the lease payments is also recognized and split between current and

non-current

liabilities accordingly.

The lease liability includes; fixed payments, variable lease payments dependent on an index or rate (initially measured using the index or rate on the lease commencement date) and in substance fixed payments. The variable aspect of variable payments are recognized when the rate or index takes effect resulting in an adjustment to the liability and

right-of-use

asset. Currently the Group’s lease portfolio does not contain variable or in substance lease payments.

F-1

The discounted lease liability is calculated where possible using the interest rate implicit in the lease or where this is not attainable the incremental borrowing rate is utilized. The incremental borrowing rate is the rate the Group would have to pay to borrow the funds necessary to obtain a similar asset under similar conditions. The Group calculates the incremental borrowing rate using risk free rate of the country where the asset is held, adjusted for length of the lease and a risk premium.

Lease payments are allocated against the principal and finance cost. Finance costs, representing the unwinding of the discount on the lease liability are charged to the income statement to produce a constant periodic rate of interest on the remaining liability.

Right-of-use

assets are measured at cost including; the discounted initial lease liability, lease payments made at or before the commencement date, any initial direct costs reduced any lease incentives received.

Right-of-use

assets are depreciated over the shorter of the

non-cancellable

lease period and any extension options that are considered reasonably certain to be taken or the useful life of the asset. The Group’s current leases run from

1-17

years.

Modifications to lease agreements result in remeasurement of the lease liability and

right-of-use

asset.

Short term leases, defined as less than one year, and also of low value are recognized on a straight-line basis in the income statement.

There are no material lease agreements where the Group acts as a lessor.

Contracts may contain both lease and

non-lease

components. The Group allocates the contract consideration based on the relative stand alone selling prices or if this is not readily determinable based on the best estimates of the stand alone selling prices.

Accounting policy applied until 30 June 2019

To the extent that the terms of a lease transferred substantially all the risks and rewards of ownership to the lessee, leases were classified as finance leases. All other leases were classified as operating leases.

Rentals payable under operating leases were charged to the income statement on a straight-line basis over the fixed term of the relevant lease. Benefits received and receivable as an incentive to enter into an operating lease were also spread on a straight-line basis over the lease term.

Foreign currencies

Foreign currency transactions are booked at the exchange rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currency are retranslated at the rates of exchange ruling at the balance sheet date. Exchange differences arising on settlement or retranslation of monetary assets and liabilities are included in the income statement.

The results of overseas subsidiaries are translated into Sterling using the average exchange rates during the year. Assets and liabilities are translated at the rates ruling at the balance sheet date. Goodwill arising on the acquisition of a foreign operation is treated as an asset of that foreign operation and as such is translated at the relevant foreign exchange rate at the balance sheet date. Exchange differences arising on this translation are recognized in the translation reserve.

Other exchange differences are recognized in the income statement in the period in which they arise except for where items are designated as hedging instruments or where there is a net investment hedge.

Retirement benefit costs

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due. The Group has no further obligations once the contributions have been paid.

Taxation

Current tax payable is based on taxable profit for the year using tax rates that have been enacted or substantively enacted by the balance sheet date. Taxable profit differs from net profit as reported in the income

F-1

statement because it excludes certain items of income or expense that are taxable or deductible in other years and further excludes items that are never taxable or deductible. Where the current tax deduction in respect of share option exercises exceeds the share option accounting charge for the period, the excess is recorded in equity rather than the income statement.

The benefit of UK research and development is recognized under the UK’s Research and Development Expenditure Credit (RDEC) scheme. The benefit is recorded as income included in profit before tax, netted against research and development expenses, as the RDEC is of the nature of a government grant.

Deferred tax is the tax expected to be payable or recoverable on differences between the carrying amount of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit, and is accounted for using the balance sheet liability method. Deferred tax liabilities are generally recognized for all taxable temporary differences and deferred tax assets are recognized to the extent that it is probable that taxable profits will be available against which deductible temporary differences can be utilized. Such assets and liabilities are not recognized if the temporary difference arises from the initial recognition of goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit.

Deferred tax liabilities are recognized for taxable temporary differences arising on investments in subsidiaries except where the Group is able to control the reversal of the temporary difference and it is probable that the temporary difference will not reverse in the foreseeable future. The Group’s liability for deferred tax is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date that are expected to apply in the period when the liability is settled or the asset is realized. Deferred tax is charged or credited in the income statement, except where it relates to items charged or credited directly to other comprehensive income or reserves, in which case the deferred tax is also dealt with in other comprehensive income or reserves respectively.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities, they relate to income taxes levied by the same taxation authority and the Group intends to settle on a net basis.

Business combinations

Business combinations are accounted for using the acquisition method. On the acquisition of a business, fair values are attributed to the identifiable assets, liabilities and contingent liabilities unless the fair value cannot be reliably measured in which case the value is subsumed into goodwill.

If the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, the Group reports provisional amounts for the items for which the accounting is incomplete. Those provisional amounts are adjusted during the measurement period or additional assets or liabilities are recognized to reflect new information obtained about facts and circumstances that existed as at the acquisition date that, if known, would have affected the amounts recognized as of that date. The measurement period is the period from the date of acquisition to the date the Group obtains complete information about facts and circumstances that existed as of the acquisition date – and is subject to a maximum of one year.

Acquisition-related costs are expensed to the consolidated income statement in the period they are incurred.

Goodwill

Goodwill represents the excess of the fair value of the consideration over the fair value of the net assets acquired. Where the fair value of the consideration is less than the fair value of the acquired net assets, the deficit is recognized immediately in the income statement as a bargain purchase.

Goodwill is not amortized, but is subject to an impairment review at least annually and is carried at cost less accumulated impairment losses. Any impairment is recognized immediately in the income statement and is not subsequently reversed.

For the purpose of impairment testing, goodwill is allocated to cash generating units (CGUs). The CGU to which goodwill has been allocated is tested for impairment annually, or more frequently when there is an indication that the carrying value may not be recoverable.

F-1

Intangible assets

Acquisition intangibles:

Acquisition intangibles comprise licence fees, customer relationships and distribution rights, patents, technology and

know-how

and trade names. These are capitalized at fair value and amortized on a straight-line basis over their estimated useful lives. The principal expected useful lives are as follows:


Licence fees		Term of licence
Customer relationships and distribution rights		4 to 10 years
Patents, technology and know-how		10 to 16 years
Trade names		8 to 11 years

Patents, technology and

know-how

assets are only amortized once the development is complete and being utilized for their intended purpose; until this point the assets are deemed to be in progress.

Other intangibles:

These comprise software and expenditure on capitalized internally developed technology. Internally developed technology costs are recognized as an asset if and only if they meet the recognition criteria set out in IAS 38 ‘Intangible Assets’:

•

the project must be technically feasible;

•

there must be the intention to complete the project;

•

there must be adequate resources to be able to complete the project;

•

the ability to use or sell the asset or product is secure;

•

the future economic benefits must exceed the costs; and

•

the ability to reliably measure costs.

Intangible assets under construction are not amortized.

The principal expected useful lives are as follows:


Software		3 to 10 years
Internally developed technology		3 to 16 years
Patents and licences		2 to 3 years

During the year ended 31 December 2021, the Group revised its estimate of the useful life of its software assets from

3 to 5 years to 3 to 10 years. Further details are shown in note 13.

Property, plant and equipment

Property, plant and equipment is stated at cost less accumulated depreciation and, where appropriate, provision for impairment in value. Cost includes the original purchase price of the asset and the costs attributable to bringing the asset to its working condition for its intended use. Depreciation is charged so as to write off the cost of assets over their estimated useful lives, using the straight-line method, as follows:


Laboratory equipment		2 to 5 years
Cell Line assets		10 years
Office fixtures, fittings and other equipment		2 to 5 years
Leasehold improvements		Term of lease

The gain or loss arising on the disposal or retirement of an asset is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognized in the income statement. Residual values of assets and their useful lives are assessed on an ongoing basis and adjusted, if appropriate, at each balance sheet date. Assets under the course of construction are not depreciated.

Impairment of property, plant and equipment and intangible assets excluding goodwill

A review is undertaken upon the occurrence of events or circumstances which indicate that the carrying amount may not be recoverable. In addition, any assets not yet available for use are tested for impairment annually.

F-1

The recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a

pre-tax

discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted. If it is not possible to determine the recoverable amount for an individual asset, the assessment is made for the asset’s cash-generating unit (CGU).

Inventories

Inventories and work in progress are stated at the lower of cost and net realizable value. Cost comprises direct materials and, where applicable, direct labour costs and an attributable portion of production overheads that have been incurred in bringing the inventories to their present location and condition. The valuation methodology is on a first in first out or a weighted average cost basis, depending on the nature of the inventory, and net realizable value represents the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution. Provision is made for obsolete, slow-moving or defective items where appropriate.

Financial assets

Financial assets and financial liabilities are recognized on the Group’s balance sheet when the Group becomes a party to the contractual provisions of the instrument. The Group’s financial assets comprise cash and cash equivalents, receivables which involve a contractual right to receive cash from external parties, and investments.

Investments

Investments in shares are held at fair market value, with any revaluation gain or loss recorded through other comprehensive income.

Trade and other receivables

Trade receivables (excluding derivative financial assets) are recognized at cost less allowances for the expected credit loss to align their cost to fair value. The provision is based on the Group’s expected credit loss.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and demand deposits and other short-term, highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of changes in value.

Financial liabilities

Financial liabilities are those which involve a contractual obligation to deliver cash to external parties at a future date.

Trade and other payables

Trade payables (excluding derivative financial liabilities) are

non-interest

bearing and are stated at cost which equates to their fair value.

Equity instruments

Equity instruments issued by the Group are recorded as the proceeds received, net of direct issue costs.

Derivative financial instruments

The Group uses forward contracts to manage the exposure to fluctuating foreign exchange rates in relation to forecast future transactions.

Derivatives are initially recognized at fair value at the date a contract is entered into and are subsequently remeasured to their fair value at each balance sheet date. The resulting gain or loss is recognized in the income statement immediately unless the derivative is designated and effective as a hedging instrument, in which event the timing of the recognition in the income statement depends on the nature of the hedge relationship.

F-1

Hedge accounting

At the inception of a hedge relationship, the Group documents the relationship between the hedging instrument and the hedged item, its effectiveness along with its risk management objectives, and its strategy for undertaking various hedge transactions. The effectiveness is repeated on an ongoing basis during the life of the instrument to ensure that the instrument remains effective.

Cash flow hedges

The Group designates certain derivatives as cash flow hedges of highly probable forecast foreign currency transactions.

The effective portion of changes in the fair value of derivatives which are designated and qualify as cash flow hedges is deferred in other comprehensive income. Gains or losses relating to the ineffective portion are recognized immediately in the income statement.

Amounts deferred in other comprehensive income are recycled to the income statement in the periods when the hedged item is recognized in the income statement.

Hedge accounting is discontinued when the Group revokes the hedging relationship, the hedging instrument expires or is sold, terminated or exercised, or it no longer qualifies for hedge accounting. Any cumulative gain or loss in other comprehensive income at that time remains in other comprehensive income and is recognized when the forecast transaction is ultimately recognized in the income statement. When a forecast transaction is no longer expected to occur, the cumulative gain or loss in other comprehensive income is recognized immediately in the income statement.

Share-based payments

Equity settled share-based payments (SBPs) are measured at fair value (excluding the effect of

non-market-based

vesting conditions) at the date of grant and is expensed on a straight-line basis over the vesting period, based on the Group’s estimate of the number of shares that will eventually vest.

Share-based payments where vesting is by reference to external performance criteria (such as growth in an external index) are measured using the Monte Carlo simulation. Those which are subject only to internal performance criteria or service conditions are measured using the Black-Scholes model.

For all schemes, the number of options expected to vest is recalculated at each balance sheet date based on expectations of leavers prior to vesting. The number of options expected to vest for schemes with internal performance criteria is also adjusted based on expectations of performance against targets. No adjustments are made for expected performance against external or ‘market-based’ targets. Charges made to the income statement in respect of equity settled share-based payments are credited to equity.

For cash settled share-based payments, the Group recognizes a liability for the services acquired, measured initially at the fair value of the liability. This liability is remeasured at each balance sheet date and at the date of settlement, with any changes in fair value recognized in the income statement.

Own shares

No gain or loss is recognized in the income statement on the purchase, sale, issue or cancellation of the Group’s own shares. Any difference between the carrying amount and the consideration is recognized in equity.

4. Critical accounting judgements and sources of estimation uncertainty

The preparation of financial statements requires management to make judgements, estimates and assumptions about the application of its accounting policies which affect the reported amounts of assets, liabilities, revenue and expenses. Actual amounts and results may differ from those estimates.

Judgements and estimates are evaluated regularly and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Any revisions to accounting estimates are recognized in the period in which the estimate is revised.

F-1

a) Key accounting judgements

Capitalization of intangible assets—internal software development

The Group

capitalizes

internal software development costs, in particular internal staff costs, relating to the enhancement of the Group’s core IT systems architecture and developments. Judgement is required in applying the capitalization criteria of IAS 38 ‘Intangible Assets’, differentiating between enhancements and maintenance. Those costs which are not treated as capital but are directly attributable to the Group’s system and process improvement project are treated as adjusting items.

In establishing the principles on which costs are capitalized, consideration is given to the nature of work being performed, whether the costs and the activities are incremental and whether the associated deliverables meet the characteristics of an asset. Processes are in place to evaluate this, and the same processes are used to confirm whether the expensed costs are related to the system and process improvement project so that classification as an adjusting item is appropriate.

A review of historical capitalized spend on software assets was undertaken, to ascertain whether they met the criteria for capitalization following adoption of the IFRIC, published in March 2021, relating to SaaS arrangements. Identifying the software assets that were impacted and the classification of costs between customization and configuration, was judgemental and technically complex, in particular around the allocation of costs to the appropriate category. As the application of the IFRIC required an historical application, the rationale of recent projects was applied to historical projects and the same estimation and judgements applied.

The review resulted in a restatement of prior year financial statements in line with the IFRIC requirements, details of which can be found in note

Capitalization of intangible assets—internally developed technology

The Group capitalizes internal costs associated with internally developed technology as intangible assets as described further in notes 3 and 13. This requires judgement to determine that the characteristics of such assets meet the relevant criteria if IAS 38 ‘Intangible Assets’ for classification as an intangible asset.

Internal costs are capitalized as internally developed technology within intangible assets which are used to generate antibodies and kits. The point at which such internal costs are capitalized as well as their magnitude (whereby the amount capitalized comprises mainly of attributable salary costs and consumables used in the manufacture process) is a key area of judgement. A key area in respect of the stage of development of internally developed technology is subject to judgement as to when a product’s future economic value justifies capitalization. Management reviews regularly these factors in order to determine that the costs meet the criteria for capitalization as intangible assets.

During the year, an impairment was booked for assets relating to AxioMx where changes in scope of the project impacted on the usability of the historical work performed, details of which can be seen in note 7 and 13.

Assessment of cash generating units (CGUs)

For the purposes of impairment testing, the Group identifies the CGU that is appropriate for the asset to be measured against if it is not possible to estimate the recoverable amount individually. The goodwill acquired in a business combination is allocated at acquisition to the CGU which is expected to benefit from that business combination.

The Group applies judgement in determining how integrated the acquired business is within the Group. Consideration is given to the product branding and ranges, whether the manufacturing and research and development has broadened since acquisition, whether sales and marketing activity is separate from the

Group

and how the business is monitored.

For the BioVision acquisition in October 2021, the Group has determined that the business is not sufficiently integrated into the Group and therefore the acquired goodwill has been tested at a BioVision CGU level. Full details can be found in note 12.

F-

b) Key sources of estimation uncertainty

Valuation of acquired intangible assets

During the current and prior periods, the Group has made a number of acquisitions (see note 29 for further details). Accounting for these in line with IFRS 3 ‘Business Combinations’ requires the use of a number of assumptions and estimates in relation to the future cash flows associated with acquisition intangibles and the use of valuation techniques in order to arrive at the fair value of the intangible assets acquired. The assumptions applied were based on the best information available to management and valuation techniques were supported by third party valuation experts.

In the current period, acquired intangibles totaling

80.6

million

were recognized in relation to the acquisition of BioVision, of which the intangible recognized in relation to the acquired technology was the most significant

(£

77.0

million).

Key assumptions in determining the valuation of this included the revenue growth rate and cash flows associated with this asset, its expected useful economic life and the expected attrition rates associated with the acquired product portfolio.

Nevertheless, the actual performance of these assets may differ from the valuations derived through this exercise.

Impairment assessment of acquired intangible assets

As described in note 13 to the consolidated financial statements, the Group holds various intangible assets. As required by IAS 36 ‘Impairment of Assets’, the Group reviews for indicators of impairment regularly by assessing the performance of the assets against qualitative and quantitative factors including the estimates used to value intangibles on acquisition or appropriate business cases.

Examples of impairment indicators are: there is a change in business strategy; asset is not meeting the acquisition forecasts; or the business is approaching the route to market differently. If any of these or other factors are present, a detailed impairment review is undertaken.

A detailed impairment assessment can be performed by either assessing the asset’s value in use or assessing the carrying value as fair value less cost to sell. Either method requires management to make a number of estimates, the most sensitive estimates being:

•

The five-year business plan – forecasted cashflows require management’s estimates of the assets’ performance in future periods and judgement as to the CGU to which the flows belong;

•

Discount rate – judgement is required in estimating the appropriate weighted average cost of capital (WACC) of a typical market participant; and

•

Market-based data – judgement is required to ensure companies and

recent

transactions are comparable in nature when estimating the fair value.

During the year ended 31 December 2021, the assets relating to Firefly BioWorks multiplex and assay technology were tested for impairment. Given the nascent state of the technology, management used the fair value less costs to sell method of assessing the recoverable amount of the intangible assets and management is satisfied that the fair value significantly exceeds the carrying value of the asset. Details can be found in note 13.

During the year to 30 June 2020, an assessment of the

acquired

intangible in respect of In Vitro monoclonal antibody production technology acquired with AxioMx, Inc. in 2015 was undertaken. This also included further smaller amounts in respect of this technology which have been

capitalized

since acquisition as certain commercial feasibility milestones had been achieved.

An appraisal of the ability to utilize at scale this technology has been undertaken whereby although technical feasibility remains valid, the challenges to realize material commercial returns have resulted in the conclusion not to pursue further active development and substantive utilization of this technology. As a result of this, the intangible asset in respect of this technology has been fully impaired.

Details of the impairment can be found in note 13.

Useful economic life (UEL) of software assets

The Group determines the UEL of all assets by estimating the length of time the asset is expected to be in use or generating income. The Group’s policy for software assets was determined as 3 to 5 years.

F-

During the

year ended 31 December 2021, the Group revised its estimate of the useful economic life of its ERP software from 5 years to 10 years, changing the Group’s policy from 3 to 5 years to 3 to 10 years. This was due to the complexity of the programme, the investment involved, and the nature of the technology implemented. See note 12 for further details.

Provision for slow-moving or defective inventory

The provision for slow-moving inventory is based on the Directors’ estimation of the future sales of each of the Group’s products over the period from the balance sheet date to the expiry date of the product. Estimated future sales are based on historical actual sales and a growth rate assumption which is derived from the average annual growth over the product life to date.

If actual unit sales growth rates differ from those estimated by management, both the level of provision against existing inventory and the rates of provision applied to inventory in future periods would need to be revised.

5. Operating segments

Products and services from which reportable segments derive their revenues

The Directors consider that there is only one core business activity and there are no separately identifiable business segments which are engaged in providing individual products or services or a group of related products and services which are subject to separate risks and returns. The information reported to the Group’s Chief Executive Officer, who is considered the chief operating decision maker, for the purposes of resource allocation and assessment of performance is based wholly on the overall activities of the Group. The Group has therefore determined that it has only one reportable segment, which is ‘sales of antibodies and related products’. The Group’s revenue and assets for this one reportable segment can be determined by reference to the Group’s income statement and balance sheet.

The Group has no individual product or customer which contributes more than 10% of its revenues.

F-

Geographical information

Revenues are attributed to regions based primarily on customers’ location. The Group’s revenue from external customers and information about its

non-current

segment assets (excluding deferred tax) is set out below:


		Revenue				Non-current assets
		Year ended 31 December 2021		Six months ended 31 December 2020		As at 31 December 2021		As at 31 December 2020 (revised*)
		£m		£m		£m		£m
The Americas			130.4		58.6		464.3		200.2
EMEA	(i)		84.3		40.2		231.8		227.8
China			58.2		27.4		8.6		6.7
Japan			18.7		9.9		0.2		0.5
Rest of Asia Pacific	(i)		23.8		11.4		59.3		61.6

			315.4		147.5		764.2		496.8


		Revenue				Non-current assets
		Year ended 30 June 2020		Year ended 30 June 2019		As at 30 June 2020 (revised*)		As at 30 June 2019 (revised*)
		£m		£m		£m		£m
The Americas			112.4		117.5		224.8		169.9
EMEA	(i)		69.3		67.1		222.3		89.5
China			39.5		39.9		7.4		3.8
Japan			18.8		16.9		0.6		0.1
Rest of Asia Pacific	(i)		20.0		18.5		61.7		0.1

			260.0		259.9		516.8		263.4

*	See note 1(d) for details related to the retrospective impact of a change in the Group’s accounting policy for cloud computing costs.

(i)

Revenues for the

sub-region

of Central Asia have been reclassified from EMEA to Asia Pacific for the year ended 31 December 2021 and the six months ended 31 December 2020. This is to better align our data reporting to sales performance and geographical location. The value attributable to Central Asia is £1.6m (six months ended 31 December 2020: £0.6m; year ended 30 June 2020: £1.5m; year ended 30 June 2019: £1.4m). The comparatives presented for 30 June 2020 and 30 June 2019 have not been updated for this change.

Revenue by type is shown below:


	Year ended 31 December 2021 £m		Six months ended 31 December 2020 £m		Year ended 30 June 2020 £m		Year ended 30 June 2019 £m
Catalogue revenue		296.4		139.0		243.1		242.8
Custom products and services		5.7		2.7		6.3		5.4
IVD		6.3		2.6		4.7		6.9
Royalties and licenses		7.0		3.2		5.9		4.8

Custom products and licensing		19.0		8.5		16.9		17.1

Total reported revenue		315.4		147.5		260.0		259.9

Because all custom products and services projects within a contract had an original expected duration of one year or less, the Group has taken advantage of the exemption not to disclose outstanding amounts in respect of uncompleted contracts.

The information reported to the Group’s Chief Executive Officer, who as described above is considered the chief operating decision maker, also includes adjusted operating profit which comprises operating profit before exceptional items, share-based payments and amortization of acquisition intangibles.

F-2

The following table presents the reconciliation of this measure to profit for the year / period:


	Note		Year ended 31 December 2021 £m			Six months ended 31 December 2020 (revised*) £m			Year ended 30 June 2020 (revised*) £m			Year ended 30 June 2019 (revised*) £m
Profit for the year / period				4.4			12.8			12.5			44.4
Tax				0.3			2.8			(4.2	)		11.2
Finance income				(0.3	)		(0.2	)		(0.7	)		(0.6	)
Finance costs				2.7			1.9			2.8			0.3

Operating profit				7.1			17.3			10.4			55.3
Exceptional items, share-based payments and amortization of acquisition intangibles		7		53.3			17.8			43.6			34.9

Adjusted operating profit for the year / period				60.4			35.1			54.0			90.2

*	See note 1(d) for details related to the retrospective impact of a change in the Group’s accounting policy for cloud computing costs.

6. Operating profit

ABCM

Abcam News